



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C07D 495/04, 471/04, 513/04 C07D 417/14, 471/04, 401/12 C07D 409/14, 307/80, 493/06 A61K 31/55, 31/47, 31/425 A61K 31/34, 31/435, 31/54	<b>A2</b>	<b>(11) International Publication Number:</b> WO 94/04537  <b>(43) International Publication Date:</b> 3 March 1994 (03.03.94)
<b>(21) International Application Number:</b> PCT/US93/07728 <b>(22) International Filing Date:</b> 16 August 1993 (16.08.93)  <b>(30) Priority data:</b> 07/933,395                      20 August 1992 (20.08.92)                      US  <b>(71) Applicant:</b> CYTOMED, INC. [US/US]; 840 Memorial Drive, Cambridge, MA 02139 (US).  <b>(72) Inventors:</b> GOLDSTEIN, David, M. ; 106 Jamestown Court, Pittsburgh, PA 15216 (US). HWANG, San-Bao ; 10 Joyce Road, Wayland, MA 01778 (US). SCANNELL, Ralph, T. ; 11 Dennis Road, Wellesley, MA 02181 (US). SHEN, T., Y. ; 303 Ednam Drive, Charlottesville, VA 22903 (US).		<b>(74) Agents:</b> ZALESKY, Cheryl, K. et al.; Kilpatrick & Cody, 1100 Peachtree Street, Suite 2800, Atlanta, GA 30309-4530 (US).  <b>(81) Designated States:</b> AU, CA, FI, HU, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> DUAL FUNCTIONAL ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE AGENTS  <b>(57) Abstract</b>  Platelet activating factor receptor antagonists of diverse structures are imparted with 5-lipoxygenase activity by adding a moiety such as a hydroxamate, hydroxyurea, oxalkane, thioalkane, quinolylmethoxy, or amidohydroxyurea to the PAF receptor antagonist at a position on the PAF antagonist molecule that demonstrates "bulk tolerance", i.e., the ability to accommodate functionality without the significant loss of PAF activity.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

**DUAL FUNCTIONAL ANTI-INFLAMMATORY AND  
IMMUNOSUPPRESSIVE AGENTS**

This invention is in the area of pharmaceutical compositions and methods for the treatment of inflammatory and immune disorders, and specifically provides novel compounds that have PAF receptor antagonist activity and inhibit the enzyme 5-lipoxygenase.

Platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycerol-3-phosphorylcholine) is a potent inflammatory phospholipid mediator with a wide variety of biological activities. PAF was initially identified as a water soluble compound released by immunoglobulin E (IgE)-sensitized rabbit basophils. It is now known that PAF is also generated and released by monocytes, macrophages, polymorphonuclear leukocytes (PMNs), eosinophils, neutrophils, natural killer lymphocytes, platelets and endothelial cells, as well as by renal and cardiac tissues under appropriate immunological and non-immunological stimulation. (Hwang, "Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms", Journal of Lipid Mediators 2, 123 (1990).) PAF causes the aggregation and degranulation of platelets at very low concentrations. The potency (active at  $10^{-12}$  to  $10^{-9}$ M), tissue level (picomoles) and short plasma half life (2-4 minutes) of PAF are similar to those of other lipid mediators such as thromboxane  $A_2$ , prostaglandins, and leukotrienes.

PAF mediates biological responses by binding to specific PAF receptors found in a wide variety of cells and tissues. Structure-activity studies on PAF and its analogs indicate that the ability of PAF to bind to these receptors is highly structure specific and stereospecific. (Shen, et al., "The Chemical and Biological Properties of PAF Agonists, Antagonists, and Biosynthetic

Inhibitors", Platelet-Activating Factor and Related Lipid Mediators, F. Snyder, Ed. Plenum Press, New York, NY 153 (1987)). While PAF mediates essential biological responses, it also appears to play a  
5 role in pathological immune and inflammatory responses. Many published studies have provided evidence for the involvement of PAF in human diseases, including arthritis, acute inflammation, asthma, endotoxic shock, pain, psoriasis,  
10 ophthalmic inflammation, ischemia, gastrointestinal ulceration, myocardial infarction, inflammatory bowel diseases, and acute respiratory distress syndrome. Animal models also demonstrate that PAF is produced or increased in certain pathological  
15 states.

The involvement of PAF in pathological inflammatory and immune states has stimulated a substantial research effort to identify PAF receptor antagonists. In 1983, a phospholipid  
20 analog referred to as CV-3988 (*rac*-3-(N-n-octadecyl-carbamoyloxy- $\theta$ -methoxypropyl-2-thiazolioethyl phosphate) was reported to have PMF receptor antagonist properties. (Terashita, et al., Life Sciences 32, 1975 (1983).) In other  
25 early work in this area, Shen, et al., (in Proc. Natl. Acad. Sci. (U.S.A.) 82, 672 (1985)), reported that kadsurenone, a neolignan derivative isolated from *Piper fotukadsura* Sieb et Zucc (a Chinese herbal plant) was a potent, specific and  
30 competitive inhibitor of PAF activity at the receptor level.

Since then, a number of compounds of diverse chemical structure have been identified as PAF receptor antagonists. Examples of active  
35 hetrazepines are disclosed in European Patent Application No. 338 993 A; Ger. Offen. DE 3,936,828; Ger. Offen. DE 4,006,471; Ger. Offen.

DE 3,701,344; Ger. Offen. DE 3,724,164; Ger. Offen. DE 3,724,031; U.S. Patent No. 4,959,361; European Patent Application No. 0 407 955 A1; and European Patent Application No. 0 367 110. A number of  
5 imidazo[2.1-a]isoquinolines with PAF receptor antagonist activity are also known, including those disclosed in United States Patent Nos. 4,910,206 and 4,992,428. Pyrrolo[1,2-c]thiazoles with PAF receptor antagonist activity are disclosed, for  
10 example, in Lave et al., Drugs of the Future, 14(9), 891 (1989); European Patent Application No. 388 309 A2; and European Patent Application No. 0 252 823 A1. Thiazolidinecarboxamides with PAF inhibiting activity are disclosed in U.S. Patent  
15 No. 4,987,132.

A number of 2,5-diaryl tetrahydrofurans with PAF receptor antagonist activity are disclosed in U.S. Patent Nos. 4,996,203, 5,001,123 and 4,539,332 to Biftu, et al. ; European Patent  
20 Application Nos. 89202593.3, 90306235.4, and 90306234.7; Journal of Biological Chemistry 260(29), 15639 (1985); and J. Pharmacol. Ther. 246, 534-541 (1988).

Leukotrienes, like PAF, are potent local  
25 mediators, playing a major role in inflammatory and allergic responses, including arthritis, asthma, psoriasis, and thrombotic disease. Leukotrienes are straight chain eicosanoids produced by the oxidation of arachidonic acid by lipxygenases.  
30 Arachidonic acid is oxidized by 5-lipoxygenase to the hydroperoxide 5-hydroperoxyeicosatetraenoic acid (5-HPETE), that is converted to leukotriene A<sub>4</sub>, that in turn can be converted to leukotriene B<sub>4</sub>, C<sub>4</sub>, or D<sub>4</sub>. The slow-reacting substance of anaphylaxis  
35 is now known to be a mixture of leukotrienes C<sub>4</sub>, D<sub>4</sub>, and E<sub>4</sub>, all of which are potent bronchoconstrictors. There has been a research effort to develop

specific antagonists or inhibitors of leukotriene synthesis, to prevent or minimize pathogenic inflammatory responses mediated by these compounds.

Leukotrienes are released simultaneously  
5 from leukocytes with PAF, possibly from a common phospholipid precursor such as 1-O-hexadecyl-2-arachidonyl-sn-glycero-phosphocholine, and upon cellular activation, act synergistically with PAF in many biological models. PAF and leukotrienes  
10 have been together associated with disease states such as asthma, arthritis, psoriasis, inflammatory bowel disease, and other inflammatory and immunological disorders.

To date, only a few functionalities have  
15 been demonstrated to consistently inhibit the enzyme 5-lipoxygenase. European Patent Application Nos. 90117171.0 and 901170171.0 disclose indole, benzofuran, and benzothiphenene lipoxygenase inhibiting compounds. Recently, it was reported  
20 that the tetrahydrothiophene derivative of L-652,731, trans-2,5-bis-(3,4,5-trimethoxyphenyl)-tetrahydrothiophene (L-653,150), is a potent PAF antagonist and a moderate inhibitor of 5-lipoxygenase. (Biftu, et al, Abstr. of 6<sup>th</sup> Int.  
25 Conf. on Prostaglandins and Related Compounds, June 3-6, 1986, Florence, Italy; U.S. Patent No. 4,757,084 to Biftu.)

Given the significant number of pathological immune and inflammatory responses that  
30 are mediated by PAF and leukotrienes, there remains a need to identify new compounds and compositions that exhibit PAF receptor antagonist activity and inhibit the enzyme 5-lipoxygenase.

Therefore, it is an object of the present  
35 invention to provide compounds that act as PAF receptor antagonists and also inhibit the enzyme 5-lipoxygenase.

It is another object of the present invention to provide pharmaceutical compositions for the treatment of pathological immune or inflammatory disorders mediated by PAF or products of 5-lipoxygenase.

It is another object of the present invention to provide a method for the treatment of pathological immune or inflammatory disorders mediated by PAF or products of 5-lipoxygenase.

### Summary of the Invention

It has been discovered that compounds with PAF receptor antagonist activity can be imparted with 5-lipoxygenase inhibiting activity by the addition of  $R^1$  to a bulk tolerating location on the compound, wherein  $R^1$  is:


(1) a hydroxamate or hydroxyurea of the formula:

$-R^2N(OM)C(O)N(R^3)R^4$ ,  $-R^2N(R^3)C(O)N(OM)R^4$ ,  
 $-R^2N(OM)C(O)R^4$ ,  $-R^2C(O)N(OM)R^4$ ,  $-N(OM)C(O)N(R^3)R^4$ ,  
 $-N(R^3)C(O)N(OM)R^4$ ,  $-N(OM)C(O)R^4$ , or  $-C(O)N(OM)R^4$ ;

(2) an amidohydroxyurea of the formula:


$-N(R^8)C(O)C(R^8)N(OM)C(O)NHR^9$ ,  
 $-C(O)N(R^8)C(R^8)N(OM)C(O)NHR^9$ ,  
 $-R^2N(R^8)C(O)C(R^8)N(OM)C(O)NHR^9$ ,  
 $-R^2C(O)N(R^8)C(R^8)N(OM)C(O)NHR^9$ ,  
 $-NHC(O)N(OM)C(R^8)C(O)N(R^8)_2$ ; or  
 $-NHC(O)N(OM)C(R^8)N(R^8)C(O)R^8$ ;

(3) an oxalkane of the structure:




wherein n and m are independently 1-4 ;

(4) a thioalkane of the structure:



or (5) a quinolylmethoxy of the structure:



$R^2$  is alkyl, alkenyl, alkynyl, alkyaryl,  
 5 aralkyl, halo lower alkyl, halo lower alkenyl, halo  
 lower alkynyl,  $-C^{1-10}$ alkyl(oxy) $C^{1-10}$ alkyl,  
 $-C^{1-10}$ alkyl(thio) $C^{1-10}$ alkyl,  $-N(R^3)C(O)$ alkyl,  
 $-N(R^3)C(O)$ alkenyl,  $-N(R^3)C(O)$ alkynyl,  
 $-N(R^3)C(O)(alkyl)oxy(alkyl)$ ,  $-N(R^3)C(O)(alkyl)thio$   
 10  $(alkyl)$ ,  $-N(R^3)C(O)N(alkyl)$ ,  $-N(R^3)C(O)N(alkenyl)$ ,  
 $-N(R^3)C(O)N(alkynyl)$ ,  $-N(R^3)C(O)N(alkyl)oxy(alkyl)$ ,  
 $-N(R^3)C(O)N(alkyl)thio(alkyl)$ ,  $-N(R^3)C(O_2)alkyl$ ,  
 $-N(R^3)C(O_2)alkenyl$ ,  $-N(R^3)C(O_2)alkynyl$ ,  
 $-N(R^3)C(O_2)(alkyl)oxy(alkyl)$ ,  
 15  $-N(R^3)C(O_2)(alkyl)thio(alkyl)$ ,  $-OC(O_2)alkyl$ ,  
 $-OC(O_2)alkenyl$ ,  $-OC(O_2)alkynyl$ ,  
 $-OC(O_2)(alkyl)oxy(alkyl)$ ,  $-OC(O_2)(alkyl)thio(alkyl)$ ,  
 $-N(R^3)C(S)alkyl$ ,  $-N(R^3)C(S)alkenyl$ ,  
 $-N(R^3)C(S)alkynyl$ ,  $-N(R^3)C(S)(alkyl)oxy(alkyl)$ ,



-N(R<sup>3</sup>)C(S)(alkyl)thio(alkyl), -N(R<sup>3</sup>)C(S)N(alkyl),  
-N(R<sup>3</sup>)C(S)N(alkenyl), -N(R<sup>3</sup>)C(S)N(alkynyl),  
-N(R<sup>3</sup>)C(S)N(alkyl)oxy(alkyl),  
-N(R<sup>3</sup>)C(S)N(alkyl)thio(alkyl), -N(R<sup>3</sup>)C(S)S(alkyl),  
5 -N(R<sup>3</sup>)C(S)S(alkenyl),  
-N(R<sup>3</sup>)C(S)S(alkynyl), -N(R<sup>3</sup>)C(S)S(alkyl)oxy(alkyl),  
-N(R<sup>3</sup>)C(S)S(alkyl)thio(alkyl),  
-SC(S)S(alkyl), -SC(S)S(alkenyl), -SC(S)S(alkynyl),  
-SC(S)S(alkyl)oxy(alkyl), or  
10 -SC(S)S(alkyl)thio(alkyl);

R<sup>3</sup> and R<sup>4</sup> are independently alkyl, alkenyl,  
alkynyl, aryl, aralkyl, alkyaryl, hydrogen, C<sub>1-6</sub>  
alkoxy-C<sub>1-10</sub> alkyl, C<sub>1-6</sub> alkylthio-C<sub>1-10</sub> alkyl, and C<sub>1-10</sub>  
substituted alkyl (wherein the substituent is  
15 independently hydroxy or carbonyl, located on any  
of C<sub>1-10</sub>);

R<sup>8</sup> is H, lower alkyl, or lower alkenyl;

R<sup>9</sup> is H, halogen, lower alkoxy, or lower  
alkyl; and

20 M is hydrogen, a pharmaceutically  
acceptable cation, or a metabolically cleavable  
leaving group.

The resulting compounds act as "dual  
function antagonists" in that they retain PAF  
25 receptor antagonist activity and also inhibit the  
enzyme 5-lipoxygenase. The invention described  
herein provides a novel route to the enhancement of  
utility of conventional PAF antagonists and  
5-lipoxygenase inhibitors.

30 According to the invention, known PAF  
antagonists of diverse structures are imparted with  
5-lipoxygenase activity by adding an iron chelating  
group such as the above-defined hydroxamate or  
hydroxyurea groups; or oxalkane, thioalkane,  
35 quinolylmethoxy, or amidohydroxyurea moieties to  
the PAF antagonist at a position on the PAF  
antagonist molecule that demonstrates "bulk

tolerance", i.e., the ability to accommodate functionality without the loss of PAF activity. The R<sup>1</sup> group is added to the PAF receptor antagonist through conventional means, including by appropriate derivatization of amino or carboxylic acid groups positioned such that the 5-LO inhibiting moiety does not significantly affect the PAF receptor antagonist activity of the molecule. With the aid of molecular modeling, the 5-lipoxygenase inhibiting moiety is optimally oriented for the substrate binding domain of 5-lipoxygenase. The length and lipophilicity of the side chain or spacer (R<sup>2</sup>) between the aromatic hydrophobic core of the PAF antagonist and the 5-lipoxygenase inhibiting moiety is optimized by conventional means, including by evaluation of standard structure-activity relationships.

In another embodiment of this invention, the utility of known PAF receptor antagonists is enhanced by the addition of substituted pyridinium heterocycles or other quaternary N-heterocycles of the formula -OR<sup>6</sup>N(R<sup>5</sup>)R<sup>6</sup>-(C<sub>5</sub>H<sub>4</sub>N)R<sup>6</sup>R<sup>7</sup>, -OR<sup>6</sup>N(CO<sub>2</sub>R<sup>5</sup>)R<sup>6</sup>-(C<sub>5</sub>H<sub>4</sub>N)R<sup>6</sup>R<sup>7</sup>, -OR<sup>6</sup>N(COR<sup>5</sup>)R<sup>6</sup>-(C<sub>5</sub>H<sub>4</sub>N)R<sup>6</sup>R<sup>7</sup>, -OR<sup>6</sup>OC(O)N(COR<sup>5</sup>)R<sup>6</sup>-(C<sub>5</sub>H<sub>4</sub>N)R<sup>6</sup>R<sup>7</sup>, -OR<sup>6</sup>O(CO)N(CO<sub>2</sub>R<sup>6</sup>)R<sup>6</sup>-(C<sub>5</sub>H<sub>4</sub>N)R<sup>6</sup>R<sup>7</sup>, or -R<sup>2</sup>(C<sub>5</sub>H<sub>4</sub>N)R<sup>6</sup>R<sup>7</sup>, wherein

R<sup>5</sup> is lower alkyl, lower alkenyl, lower alkynyl, hydroxyl, hydrogen, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, aralkyl, or aryl;

R<sup>6</sup> is lower alkyl, lower alkenyl, lower alkynyl, aralkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, or aryl; and

R<sup>7</sup> is an organic or inorganic anion.

These quaternized heterocycles increase the water solubility of the PAF receptor antagonist, allowing the compound to be administered by injection or

- 9 -

infusion intravenously. Further, the addition of the substituted pyridinium heterocycle or other quaternary N-heterocycle to the PAF antagonist in many cases enhances the PAF antagonist activity of the compound.

In the circumstance that the addition of R<sup>1</sup> decreases the PAF receptor antagonist activity of the conventional agent being modified, PAF antagonist activity may be restored, or augmented, by the addition of a substituted pyridinium heterocycle or other quaternary N-heterocycle to an appropriate position on the molecule.

A method to treat disorders mediated by PAF or leukotrienes is also disclosed, that includes administering an effective amount of one or more of the compounds described herein or a pharmaceutically acceptable salt or derivative thereof, optionally in a pharmaceutically acceptable carrier.

The compounds disclosed herein can also be used as research tools to study the structure and location of PAF receptors as well as biological pathways involving leukotrienes.

#### Brief Description of the Figures

Figure 1 is a schematic illustration of PAF receptor antagonist hetrazepines modified to exhibit 5-lipoxygenase inhibiting activity. R<sup>10</sup> is hydrogen, alkyl, aryl, alkoxy, nitro, halogen, amino, alkylamino, dialkylamino, arylamino, diarylamino, heteroaryl amino, diheteroaryl amino. R<sup>11</sup> is hydrogen or alkyl.

Figure 2 is a schematic illustration of PAF receptor antagonist dimethoxyphenylethyl-phenylimidazo-[2.1-a]isoquinolines modified to exhibit 5-lipoxygenase inhibiting activity.

- 9a -

Figure 3 is a schematic illustration of PAF receptor antagonist pyrrolo[1,2]thiazoles modified to exhibit 5-lipoxygenase inhibiting activity.  $R^{12}$  is H, alkyl, aryl, or aralkyl.

5

Figure 4 is a schematic illustration of PAF receptor antagonist thiazolidinecarboxamides

modified to exhibit 5-lipoxygenase inhibiting activity.

Figure 5 is a schematic illustration of PAF receptor antagonist dihydropyridines modified to exhibit 5-lipoxygenase inhibiting activity.

Figure 6 is a schematic illustration of PAF receptor antagonist propenylcarboximides modified to exhibit 5-lipoxygenase inhibiting activity.

Figures 7 and 7a are schematic illustrations of PAF receptor antagonist kadsurenone analogs modified to exhibit 5-lipoxygenase inhibiting activity.

Figure 8 is a schematic illustration of 1,5-dioxabicyclo-[3.3.0]octanes with PAF receptor antagonist and 5-lipoxygenase inhibiting activity.

#### Detailed Description of the Invention

The term alkyl, as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic hydrocarbon of  $C_1$  to  $C_{10}$ .

The term lower alkyl, as used herein, and unless otherwise specified, refers to a  $C_1$  to  $C_6$  saturated straight, branched, or cyclic (in the case of  $C_{5,6}$ ) hydrocarbon, and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.

The term alkenyl, as referred to herein, and unless otherwise specified, refers to a straight, branched, or cyclic (in the case of  $C_{5,6}$ ) hydrocarbon of  $C_2$  to  $C_{10}$  with at least one double bond.

The term lower alkenyl, as referred to herein, and unless otherwise specified, refers to

an alkenyl group of C<sub>2</sub> to C<sub>6</sub>, and specifically includes vinyl, and allyl.

The term lower alkylamino refers to an amino group that has one or two lower alkyl substituents.

The term alkynyl, as referred to herein, and unless otherwise specified, refers to a C<sub>2</sub> to C<sub>10</sub> straight or branched hydrocarbon with at least one triple bond.

The term lower alkynyl, as referred to herein, and unless otherwise specified, refers to a C<sub>2</sub> to C<sub>6</sub> alkynyl group, specifically including acetylenyl and propynyl.

The term aryl, as used herein, and unless otherwise specified, refers to phenyl or substituted phenyl, wherein the substituent is halo lower alkoxy or lower alkyl.

The term alkoxy, as used herein, and unless otherwise specified, refers to a moiety of the structure -O-alkyl.

The term heteroaryl, as used herein, and unless otherwise specified, refers to an aromatic moiety that includes at least one sulfur, oxygen, or nitrogen in the aromatic ring. Nonlimiting examples are furyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbozolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, pyrazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl.

- 12 -

The term halo, as used herein, includes fluoro, chloro, bromo, and iodo.

The term halo lower (alkyl, alkenyl, or alkynyl) refers to a lower (alkyl, alkenyl, or alkynyl) group in which at least one of the hydrogens in the group has been replaced with a halogen atom.

The term aralkyl refers to an aryl group with an alkyl substituent.

The term alkaryl refers to an alkyl group that has an aryl substituent.

The term organic or inorganic anion refers to an organic or inorganic moiety that carries a negative charge and can be used as the negative portion of a salt, and in particular, an organic salt such as an organic amine, including a quaternary amine.

The term "pharmaceutically acceptable cation" refers to an organic or inorganic moiety that carries a positive charge and that can be administered in association with a pharmaceutical agent, for example, as a countercation in a salt.

The term "metabolically cleavable leaving group" refers to a moiety that can be cleaved in vivo from the molecule to which it is attached, and includes but is not limited to an organic or inorganic anion, a pharmaceutically acceptable cation, acyl (for example C(O)-alkyl, including acetyl, propionyl, butyryl, and succinyl) alkyl, phosphate, sulfate, and sulfonate.

The term "enantiomerically enriched composition or compound" refers to a composition or compound that includes at least 95% by weight of a single enantiomer of the compound.

The term PAF receptor antagonist refers to a compound that binds to a PAF receptor with a binding constant of 10  $\mu$ M or lower.

The term 5-lipoxygenase inhibitor refers to a compound that inhibits the enzyme at 10  $\mu$ M or lower in a broken cell system.

The term pharmaceutically active derivative  
5 refers to any compound that upon administration to the recipient, is capable of providing directly or indirectly, the compounds disclosed herein.

I. Structure and Synthesis of the Active Compounds

10 A. General Procedure for Synthesis of Hydroxyurea and Hydroxamate 5-Lipoxygenase Inhibiting Moieties

In one embodiment, compounds with PAF  
activity can be modified to impart 5-lipoxygenase  
15 activity to the compound by the addition of a group that has a hydroxamic acid function  
(-N(OH)C(O)-) or a hydroxyurea function  
(-N(OH)C(O)NH-). The hydroxamic acid or  
hydroxyurea function can be attached to the PAF  
20 antagonist molecule through a wide variety of means known or readily ascertainable to those of skill in the art of organic synthesis. For example, amines on the PAF antagonist molecule can be converted to hydroxyureas by known procedures, as described in  
25 more detail below. Carboxylic acids or carboxylic acid derivatives or precursors can easily be converted into hydroxamic acids.


Alternatively, other groups on the PAF  
antagonist molecule can be converted by standard  
30 techniques into amine or carboxylic acid functions that, in turn, can be converted into a hydroxyurea or hydroxamic acid, respectively.

The hydroxamic acid and hydroxyurea  
moieties can be attached to the PAF antagonist  
35 molecule through either end of the moiety; i.e., hydroxamic acids (-N(OH)C(O)-) can be attached through the carbonyl or the nitrogen (referred to




below as a "reverse" hydroxamic acid), and hydroxyureas (-N(OH)C(O)NH-) can be attached through the N(H) or N(OH) (referred to below as a "reverse" hydroxyurea) moiety.

- 5 A general procedure for preparing a hydroxyurea is:




- wherein R is a PAF receptor antagonist with or without a linking moiety, and R' is a moiety as  
10 defined in detail above.


A general procedure for preparing a reverse hydroxyurea is:



- A general procedure for preparing a  
15 hydroxamic acid is:



A general procedure for preparing a reverse hydroxamic acid is:



5 **B. General Procedure for Synthesis of Amidohydroxyurea 5-Lipoxygenase Inhibiting Moieties**


In a second embodiment, compounds with PAF activity can be modified to impart 5-lipoxygenase activity to the compound by the addition of a group  
10 that has an amidohydroxyurea moiety such as

- N(R<sup>8</sup>)C(O)C(R<sup>8</sup>)N(OM)C(O)NHR<sup>9</sup>,  
 -C(O)N(R<sup>8</sup>)C(R<sup>8</sup>)N(OM)C(O)NHR<sup>9</sup>,  
 -R<sup>2</sup>N(R<sup>8</sup>)C(O)C(R<sup>8</sup>)N(OM)C(O)NHR<sup>9</sup>,  
 -R<sup>2</sup>C(O)N(R<sup>8</sup>)C(R<sup>8</sup>)N(OM)C(O)NHR<sup>9</sup>,  
 15 -NHC(O)N(OM)C(R<sup>8</sup>)C(O)N(R<sup>8</sup>)<sub>2</sub>; or  
 -NHC(O)N(OM)C(R<sup>8</sup>)N(R<sup>8</sup>)C(O)R<sup>8</sup>.

The amidohydroxyurea moiety can be attached to the PAF antagonist molecule through a wide variety of means readily ascertainable to those of skill in  
 20 the art of organic synthesis. The amidohydroxyurea moiety can be attached to the PAF receptor antagonist molecule through a spacer, R<sup>2</sup>, as desired.

- 16 -


A general procedure for preparing  
amidohydroxyurea moieties is:







**C. General Procedure for Synthesis of  
Oxaalkane and Thioalkane 5-Lipoxygenase  
Inhibiting Moieties**

Oxaalkanes and thioalkanes can be prepared  
as described by Crawley, et al., J. Med. Chem., **35**,  
2600-2609 (1992), and illustrated below, by  
conversion of the PAF receptor antagonist into a  
Grignard reagent or lithium salt, followed by  
reaction with the appropriate cyclic ketone.

- 17 -






- 19 -

D. General Procedure for Synthesis of  
Quinolylmethoxy 5-Lipoxygenase Inhibiting  
Moieties

Quinolylmethoxy moieties can be prepared as  
described by Musser, et al., J. Med. Chem., 35,  
2501-2524 (1992), and references cited therein, as  
illustrated below.



- 20 -

**E. Compounds with PAF Antagonist Activity**

Any compound that has PAF receptor antagonist activity can be modified according to the present invention to impart 5-lipoxygenase inhibiting activity to that compound. It is generally known that there are locations on biologically active molecules, including PAF receptor antagonists active, that cannot be modified without compromising the desired biological activity. It is also generally known that there are locations on biologically active compounds that can tolerate the addition of moieties without significant loss of the desired biological activity. These areas of the compounds are referred to as "bulk tolerating" locations.

In another embodiment, the invention is a method to impart 5-lipoxygenase inhibiting activity to PAF receptor antagonists other than 2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; 2,5-diaryl-1,3-oxathiolanes; 2,5-diaryl tetrahydrothiophenes, tetrahydrofurans, and pyrrolidines; 1,3-diaryl cyclopentanes; and 2,4-diaryl tetrahydrothiophenes, tetrahydrofurans and pyrrolidines.

According to the present invention, R<sup>1</sup> groups are added to PAF receptor antagonists at bulk tolerating locations on the molecule. The bulk tolerating areas are easily identified by analysis of the PAF receptor antagonist activity of the compound of interest, and the compound as modified by the addition of chemical moieties at various locations on the molecule. A large amount of information available regarding structure-activity relationships for a variety of PAF receptor antagonists is available and can be used to identify bulk tolerating areas.

- 21 -

The invention is not limited to the modification of specific PAF receptor antagonists, but is instead a general method. Below are provided specific detailed examples of the  
5 modification of a number of PAF receptor antagonists. For convenience, Examples 1-7 provide detailed descriptions for methods to convert conventional PAF receptor antagonists into dual  
10 function antagonists through the addition of hydroxamate or hydroxyurea moieties to the compounds. It should be understood that these PAF antagonists can also be modified by the addition of oxalkane, thioalkane, quinolylmethoxy, or  
amidohydroxyurea moieties.

15 Given these detailed instructions, one of ordinary skill in the art will be able to modify other PAF antagonist molecules in a similar fashion. All modifications of PAF antagonists at bulk tolerating areas with the disclosed  
20 5-lipoxygenase inhibiting moieties are considered within the scope of this invention.

Equivalent or similar reagents and conditions can be substituted for those described below without departing from the scope of the  
25 invention.


**Example 1: Preparation of Hetrazepines with PAF and 5-Lipoxygenase Inhibiting Activity**

A variety of hetrazepines with PAF receptor antagonist activity are known. Nonlimiting  
30 examples of active hetrazepines that can be modified using the disclosed method are disclosed in European Patent Application No. 338 993 A; Ger. Offen. DE 3,936,828; Ger. Offen. DE 4,006,471; Ger. Offen. DE 3,701,344; Ger. Offen. DE 3,724,164; Ger.  
35 Offen. DE 3,724,031; US 4,959,361; European Patent Application No. 0 407 955 A1; and European Patent Application No. 0 367 110.







Figure 1 is an illustration of the chemical structures of nonlimiting examples of hetrazepines modified to include hydroxamate and hydroxyurea moieties. Starting from the known thienotri-  
 5 azolodiazepine 1 both hydroxamate and hydroxyurea moieties can be incorporated onto an area of the molecule where a great variety of functionalization has clearly been shown to be tolerated. Thus, as shown in Scheme 1 below, ester 1 is saponified to  
 10 carboxylic acid 2 with hydroxide. Conversion of

Scheme 1



Scheme 1



- 24 -

acid 2 to the acid chloride followed by addition of methyl hydroxylamine provides the desired hydroxamate 3. Alternatively, starting from the known thienotriazolodiazepine 4, the primary amine is converted into a hydroxyurea by sequential reaction with triphosgene and methyl hydroxylamine to furnish 5. In the same manner, hydroxamates and hydroxyurea containing hetrazepines are synthesized with modified spacer groups between the thiophene ring and the iron chelating moiety. Some additional examples include but are not limited to compounds of types 6-9.

Specific nonlimiting examples of dual function hetrazepines that can be prepared according to this process are:

Compound 3 (Hydroxamic Acid)

6-(2-chlorophenyl)-3-(N-hydroxy-N-methyamido)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f][1,3]-imidazolo[3,2-a][1,4]-diazepine;

20 Derivatives of Compound 3:

6-(2-chlorophenyl)-3-(N-ethyl-N-hydroxyamido)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f][1,3]-imidazolo[3,2-a][1,4]-diazepine;

25 6-(2-chlorophenyl)-3-(N-hydroxy-N-propylamido)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f][1,3]-imidazolo[3,2-a][1,4]-diazepine;

6-(2-chlorophenyl)-3-(N-cyclopropyl-N-hydroxyamido)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f][1,3]-imidazolo[3,2-a][1,4]-diazepine;

Compound 5 (Hydroxyurea):

6-(2-chlorophenyl)-3-(N-hydroxy-N-methylureidyl-methyl)-11-methyl-cyclopentyl[1,5:4,5]thieno-[3,2-f][1,3]-imidazolo[3,2-a][1,4]-diazepine;

5 Derivatives of Compound 5:

6-(2-chlorophenyl)-3-(N-ethyl-N-hydroxyureidyl-methyl)-11-methyl-cyclopentyl[1,5:4,5]thieno-[3,2-f][1,3]imidazolo-[3,2-a][1,4]-diazepine;

10 6-(2-chlorophenyl)-3-(N-hydroxy-N-propylureidyl-methyl)-11-methyl-cyclopentyl[1,5:4,5]thieno-[3,2-f][1,3]imidazolo-[3,2-a][1,4]-diazepine;

6-(2-chlorophenyl)-3-(N-butyl-N-hydroxyureidyl-methyl)-11-methyl-cyclopentyl[1,5:4,5]thieno-[3,2-f][1,3]imidazolo-[3,2-a][1,4]-diazepine;

15 The Reverse Hydroxyurea of Compound 5:

6-(2-chlorophenyl)-3-(N-hydroxy-N'-methylureidyl-methyl)-11-methylcyclopentyl[1,5:4,5]thieno-[3,2-f][1,3]-imidazolo[3,2-a][1,4]-diazepine;

Derivatives of the Reverse Hydroxyurea of Compound20 5

6-(2-chlorophenyl)-3-(N'-benzyl-N-hydroxyureidyl-methyl)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f]-[1,3]imidazolo-[3,2-a][1,4]-diazepine;

25 6-(2-chlorophenyl)-3-(N-hydroxy-N'-phenylureidyl-methyl)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f]-[1,3]imidazolo[3,2-a][1,4]-diazepine;

6-(2-chlorophenyl)-3-(N'-butyl-N-hydroxyureidyl-methyl)-11-methyl-cyclopentyl[1,5:4,5]thieno-[3,2-f][1,3]imidazolo[3,2-a][1,4]-diazepine;

- 26 -

6-(2-chlorophenyl)-3-(N-hydroxyureidylmethyl)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f][1,3]-imidazolo[3,2-a][1,4]-diazepine;

Hydroxamic acid derivatives of Compound 5:

5 6-(2-chlorophenyl)-3-(N-acetyl-N-hydroxyamino-methyl)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f]-[1,3]imidazolo[3,2-a][1,4]-diazepine;

6-(2-chlorophenyl)-3-(N-benzoyl-N-hydroxyamino-methyl)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f]-  
10 [1,3]imidazolo[3,2-a][1,4]-diazepine;

6-(2-chlorophenyl)-3-(N-hydroxy-N-propanoylamino-methyl)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f]-[1,3]imidazolo[3,2-a][1,4]-diazepine;

6-(2-chlorophenyl)-3-(N-butanoyl-N-hydroxyamino-methyl)-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f]-  
15 [1,3]imidazolo[3,2-a][1,4]-diazepine;

Compound 6 (Hydroxyurea):

(8-R)-6-(2-chlorophenyl)-3-(N'-hydroxy-N'-methyl-carboxamido)-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyridyl[4,3:4,5]thieno[3,2-f][1,3]imidazolo[3,2-a]-  
20 [1,4]-diazepine;

Derivatives of Compound 6:

(8-R)-6-(2-chlorophenyl)-3-(N'-ethyl-N'-hydroxy-carboxamido)-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyridyl[4,3:4,5]thieno[3,2-f][1,3]imidazolo[3,2-a]-  
25 [1,4]-diazepine;

(8-R)-6-(2-chlorophenyl)-3-(N'-hydroxy-N'-phenyl-carboxamido)-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyridyl[4,3:4,5]thieno[3,2-f][1,3]imidazolo[3,2-a]-  
30 [1,4]-diazepine;

- 27 -

(8-R)-6-(2-chlorophenyl)-3-(N'-cyclopropyl-N'-hydroxycarboxamido)-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyridyl[4,3:4,5]thieno[3,2-f][1,3]-imidazolo[3,2-a][1,4]-diazepine;

5    Compound 8 (Hydroxyurea):

6-(2-chlorophenyl)-3-N-(N'-hydroxycarboxamido)-11-methyl-2,3,4-dihydropyrrollo[4,3:4,5]thieno[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]-diazepine;

Derivatives of Compound 8:

10    6-(2-chlorophenyl)-3-N-(N'-hydroxy-N'-methyl-carboxamido)-11-methyl-2,3,4-dihydropyrrollo-[4,3:4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine;

15    6-(2-chlorophenyl)-3-N-(N'-ethyl-N'-hydroxy-carboxamido)-11-methyl-2,3,4-dihydropyrrollo[4,3:4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine;

20    6-(2-chlorophenyl)-3-N-(N'-hydroxy-N'-phenyl-carboxamido)-11-methyl-2,3,4-dihydropyrrollo[4,3:4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine;

25    6-(2-chlorophenyl)-3-N-(N'-butyl-N'-hydroxy-carboxamido)-11-methyl-2,3,4-dihydropyrrollo[4,3:4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine;

Compound 9 (Hydroxamic Acid):

(8-R)-6-(2-chlorophenyl)-5-(N'-hydroxycarboxamido-methyl)-8,11-dimethylthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine;

- 28 -

Derivatives of Hydroxamic acid 9:

(8-R)-6-(2-chlorophenyl)-5-(N'-hydroxy-N'-methyl-carboxamidomethyl)-8,11-dimethylthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine;

5 (8-R)-6-(2-chlorophenyl)-5-(N'-p-chlorophenyl-N'-hydroxycarboxamidomethyl)-8,11-dimethylthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine;

(8-R)-6-(2-chlorophenyl)-5-(N'-hydroxy-N'-propyl-carboxamidomethyl)-8,11-dimethylthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine; and  
10

(8-R)-6-(2-chlorophenyl)-5-(N'-butyl-N'-hydroxycarboxamidomethyl)-8,11-dimethylthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine.





15 **Example 2: Preparation of Dimethoxyphenyl-ethylphenylimidazo[2.1-a]isoquinolines with PAF and 5-Lipoxygenase Inhibiting Activity.**

A number of imidazo[2.1-a]isoquinolines with PAF receptor antagonist activity are also  
20 known. Nonlimiting examples of imidazo-[2.1-a]isoquinolines PAF receptor antagonists that can be modified according to the present invention to exhibit 5-lipoxygenase inhibiting activity are disclosed in United States Patent Nos. 4,910,206  
25 and 4,992,428.

Figure 2 is an illustration of the chemical structures of nonlimiting examples of imidazo-[2.1-a]isoquinolines modified to include hydroxamate and hydroxyurea moieties. These  
30 compounds can be prepared as described in detail in Scheme 2 below.


- 29 -

Scheme 2







Scheme 2



Scheme 2  
Reverse Hydroxyurea of 14





- 33 -

Briefly, the dihydroimidazole 10 is condensed with the nitro ester 11 to give the dihydroimidazo-[1,2-a]isoquinoline 12. Reduction of the nitro group to the amine with zinc metal yields the amino heterocycle 13 which is treated first with triphosgene and then with a hydroxylamine (methyl hydroxylamine was used in this example but any substitution is possible) to give the hydroxyurea 14.

10 In a similar fashion the hydroxamic acid can be prepared starting from the dihydroimidazole 10 and the cyano ester 15. The resultant dihydroimidazoquinoline can then be hydrolyzed to the acid 17 which is converted via its acid chloride to the hydroxamic acid 18.

The reverse hydroxyurea of compound 14 can be prepared by reduction of the nitro ester 12 to the corresponding hydroxylamine, that is reacted with  $\text{CH}_3\text{NCO}$  to provide the product hydroxyurea.

20 Nonlimiting examples of dual function imidazo[2.1-a]isoquinolines that can be prepared according to this process are:

Compound 14 (Hydroxyurea):

25 5-[4'-(3-(N-hydroxy-N-methylureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]-isoquinoline;

Derivatives of Compound 14:

30 5-[4'-(3-(N-hydroxyureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydro-imidazo[2,1-a]-isoquinoline;

5-[4'-(3-(N-ethyl-N-hydroxyureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]-isoquinoline;

- 34 -

5-[4'-(3-(N-hydroxy-N-propylureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]-isoquinoline;

5 5-[4'-(3-(N-cyclopropyl-N-hydroxyureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline;

Reverse Hydroxyurea of Compound 14:

10 5-[4'-(3-(N'-methyl-N-hydroxyureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydro-imidazo[2,1-a]-isoquinoline;

Derivatives of Reverse hydroxyurea 14:

5-[4'-(3-(N-hydroxyureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydro-imidazo[2,1-a]-isoquinoline;

15 5-[4'-(3-(N'-ethyl-N-hydroxyureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]-isoquinoline;

20 5-[4'-(3-(N-hydroxy-N'-phenylureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]-isoquinoline;

5-[4'-(3-(N'-butyl-N-hydroxyureidyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]-isoquinoline;

Compound 18 (Hydroxamic Acid):

25 5-[4'-(3-(N-methyl-N-hydroxycarboxamido)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline;

- 35 -

Derivatives of Hydroxamic acid 18:

5-[4'-(3-(N-hydroxycarboxamido)-4,5-dimethoxy-phenyl-ethyl)-phenyl]-2,3-dihydro-imidazo[2,1-a]-isoquinoline;

5 5-[4'-(3-(N-ethyl-N-hydroxycarboxamido)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo-[2,1-a]isoquinoline;

5-[4'-(3-(N-propyl-N-hydroxycarboxamido)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo-  
10 [2,1-a]isoquinoline; and

5-[4'-(3-(N-butyl-N-hydroxycarboxamido)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo-[2,1-a]isoquinoline;

15 **Example 3:** Preparation of Pyrrolo[1,2-c]thiazole with PAF and 5-Lipoxygenase Inhibiting Activity

Pyrrolo[1,2-c]thiazoles with PAF receptor antagonist activity can also be modified using the disclosed process to impart 5-lipoxygenase  
20 inhibiting activity to the molecules. Nonlimiting examples of pyrrolo[1,2-c]thiazoles that can be converted into dual function antagonists are described, for example, in Lave et al., Drugs of the Future, 14(9), 891 (1989); European Patent  
25 Application No. 388 309 A2; and European Patent Application No. 0 252 823 A1.


Figure 3 is an illustration of nonlimiting examples of pyrrolo[1,2-c]thiazoles modified through the addition of hydroxamate or hydroxyurea  
30 groups to impart 5-lipoxygenase inhibiting activity to the compound. These compounds can be synthesized as illustrated in Scheme 3 below, using pyrrolo[1,2-c]thiazole carboxylic acid 19 as the starting material. The carboxylic acid 19 is

converted to the amide 20 by treatment with oxalyl chloride followed by ammonia. Reduction of the amide with lithium aluminum hydride provides the amine 21. Treatment of the amine 21 with  
5 triphosgene followed by methyl hydroxylamine hydrochloride gives the hydroxyurea 22. In a second pathway, treatment of the carboxylic acid 19 with oxalyl chloride followed by a nitroaniline gives the amide 23. Reduction of the nitro group  
10 with sodium dithionite then yields the aniline 24. Treatment with triphosgene and then with a hydroxylamine such as methyl hydroxylamine hydrochloride then yields the hydroxyurea 25.


According to pathway three of Scheme 3,  
15 pyrrolo[1,2-c]carboxylic acid 19 is treated with oxalyl chloride followed by a hydroxylamine to provide the pyrrolo[1,2-c]thiazole hydroxamic acid 26.

Scheme 3

1.




2.





Scheme 3



The preparation of hydroxyurea amides is illustrated in pathway 4 of Scheme 3. In this case the pyrrolo[1,2-c]thiazole carboxylic acid 19 is treated with oxalyl chloride and a

5 carbethoxyaniline to produce the amide 27. Hydrolysis of the ester in compound 27 yields the acid 28 which is then converted to the hydroxamic acid 29.

Specific nonlimiting examples of dual  
10 function pyrrolo[1,2-c]thiazoles that can be prepared according to this process are:

Compound 22 (Hydroxyurea):

7-(N-hydroxy-N-methylureidylmethyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole;

15 Derivatives of Hydroxyurea 22:

7-(N-hydroxyureidylmethyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole;

7-(N-ethyl-N-hydroxyureidylmethyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole;

20 7-(N-hydroxy-N-phenylureidylmethyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole;

7-(N-cyclopropyl-N-hydroxyureidylmethyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole;

Reverse Hydroxyurea of Compound 22:

25 7-(N-hydroxy-N'-methylureidylmethyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole;

Derivatives of Reverse Hydroxyurea of Compound 22:

7-(N-hydroxyureidylmethyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole;

7-(N'-benzyl-N-hydroxyureidylmethyl)-3-(3-pyridyl)-  
1H,3H-pyrrolo[1,2-c]thiazole;

7-(N-hydroxy-N'-propylureidylmethyl)-3-(3-pyridyl)-  
1H,3H-pyrrolo[1,2-c]thiazole;

5 7-(N'-butyl-N-hydroxyureidylmethyl)-3-(3-pyridyl)-  
1H,3H-pyrrolo[1,2-c]thiazole;

Compound 25 (Hydroxyurea):

N-(4-(N-hydroxy-N-methylureidylphenyl)-3-(3-pyri-  
dyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

10 Derivatives of Hydroxyurea 25:

N-(4-(N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-  
pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(4-(N-ethyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-  
1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

15 N-(4-(N-hydroxy-N-phenylureidylphenyl)-3-(3-  
pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
carboxamide;

N-(4-(N-butyl-N-hydroxyureidylphenyl)-3-(3-  
pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
20 carboxamide;

N-(3-(N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-  
pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(3-(N-hydroxy-N-methylureidylphenyl)-3-(3-  
pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
25 carboxamide;

- 41 -

N-(3-(N-ethyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

5 N-(3-(N-hydroxy-N-propylureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(3-(N-cyclopropyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

10 N-(2-(N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(2-(N-hydroxy-N-methylureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

15 N-(2-(N-ethyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

20 N-(2-(N-hydroxy-N-phenylureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(2-(N-butyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

Reverse Hydroxyurea 25:

25 N-(4-(N-hydroxy-N'-methylureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

Derivatives of hydroxyurea 25:

- N-(4-(N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- 5     N-(4-(N'-ethyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- N-(4-(N-hydroxy-N'-propylureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- 10    N-(4-(N'-butyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- N-(3-(N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- 15    N-(3-(N-hydroxy-N'-methylureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- N-(3-(N'-benzyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- 20    N-(3-(N'-cyclopropyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- N-(3-(N'-butyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- 25    N-(2-(N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(2-(N'-ethyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

5 N-(2-(N-hydroxy-N'-phenylureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(2-(N'-cyclopropyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

10 N-(2-(N'-butyl-N-hydroxyureidylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

Hydroxamic acid 26:

15 3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-N-hydroxy-N-methylcarboxamide;

Derivatives of hydroxamic acid 26:

3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-N-ethyl-N-hydroxycarboxamide;

20 3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-N-hydroxy-N-propylcarboxamide;

3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-N-butyl-N-hydroxycarboxamide;

Hydroxamic acid 29:

25 N-(4-(N-hydroxy-N-methylcarboxamidophenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

Derivatives of hydroxyurea 29:

- N-(4-(N-hydroxycarboxamidophenyl)-3-(3-pyridyl)-1H,  
3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- 5     N-(4-(N-ethyl-N-hydroxycarboxamidophenyl)-3-(3-  
pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
carboxamide;
- N-(4-(N-hydroxy-N-phenylcarboxamidophenyl)-3-(3-  
pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
carboxamide;
- 10    N-(4-(N-cyclopropyl-N-hydroxycarboxamidophenyl)-3-  
(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
carboxamide;
- N-(3-(N-hydroxycarboxamidophenyl)-3-(3-pyridyl)-1H,  
3H-pyrrolo[1,2-c]thiazole-7-carboxamide;
- 15    N-(3-(N-hydroxy-N-methylcarboxamidophenyl)-3-(3-  
pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
carboxamide;
- N-(3-(N-ethyl-N-hydroxycarboxamidophenyl)-3-(3-  
pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
20    carboxamide;
- N-(3-(N-hydroxy-N-propylcarboxamidophenyl)-3-(3-  
pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
carboxamide;
- N-(3-(N-butyl-N-hydroxycarboxamidophenyl)-3-(3-  
25    pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-  
carboxamide;
- N-(2-(N-hydroxycarboxamidophenyl)-3-(3-pyridyl)-1H,  
3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(2-(N-hydroxy-N-methylcarboxamidophenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

5 N-(2-(N-ethyl-N-hydroxycarboxamidophenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide;

N-(2-(N-hydroxy-N-phenylcarboxamidophenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide; and

10 N-(2-(N-butyl-N-hydroxycarboxamidophenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide.

15 **Example 4: Preparation of Thiazolidine-carboxamides with PAF and 5-Lipoxygenase Inhibiting Activity**


Nonlimiting examples of thiazolidine-carboxamides with PAF receptor antagonist activity that can be modified to exhibit 5-lipoxygenase inhibiting activity are disclosed in U.S. Patent  
20 No. 4,987,132. Illustrative examples of thiazolidinecarboxamides modified to have 5-lipoxygenase inhibiting activity are illustrated in Figure 4. These compounds can be prepared as exemplified in Scheme 4 below. The alkyl amine 30  
25 is treated with triphosgene and methyl hydroxylamine to provide the hydroxyurea 31. Reaction of the hydroxyurea with carbethoxypiperazine under basic conditions gives the alkyl piperazine 34. Esterification of  
30 thiazolidine 36 with the piperazine 34 gives the dual function antagonist 37.

The preparation of the hydroxamic acid dual function antagonist 38 starts with the carboxylic acid 32 which is converted to the acid chloride and



treated with methyl hydroxylamine to provide the hydroxamic acid 33. Treatment of 33 with carbethoxypiperazine under basic conditions yields the alkyl piperazine 35. Esterification of the  
5 thiazolidine carboxylic acid 36 with the piperazine 35 yields the dual function antagonist 38.

Scheme 4



Nonlimiting examples of dual function thiazolidinecarboxamides that can be prepared according to this process are:

Compound 37 (Hydroxyurea):

- 5 1-(3-(4'-N-hydroxy-N-methylureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;

Derivatives of Hydroxyurea 37:

- 10 1-(3-(4'-N-hydroxylureidylphenyl)propyl)-4-[2-(3-pyridyl)-thiazolidine-4-yl-carbonyl]piperazine;
- 1-(3-(4'-N-ethyl-N-hydroxyureidylphenyl)phenyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;
- 15 1-(3-(4'-N-hydroxy-N-propylureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;
- 1-(3-(4'-N-cyclopropyl-N-hydroxyureidylphenyl)-propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;
- 20 1-(3-(3'-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)-thiazolidine-4-yl-carbonyl]piperazine;
- 1-(3-(3'-N-hydroxy-N-methylureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;
- 25 1-(3-(3'-N-ethyl-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;

- 49 -

- 1-(3-(3'-N-hydroxy-N-phenylureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;
- 5 1-(3-(3'-N-butyl-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;
- 1-(3-(2'-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;
- 10 1-(3-(2'-N-hydroxy-N-methylureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;
- 1-(3-(2'-N-ethyl-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;
- 15 1-(3-(2'-N-hydroxy-N-phenylureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine; and
- 1-(3-(2'-N-butyl-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine.
- 20

Reverse Hydroxyurea of Compound 37:

- 1-(3-(4'-N'-ethyl-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;
- 25 Derivatives of Reverse Hydroxyurea 37:
- 1-(3-(4'-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)-thiazolidine-4-yl-carbonyl]piperazine;

- 1-(3-(4'-N'-benzyl-N-hydroxyureidylphenyl)propyl)-  
4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-  
piperazine;
- 1-(3-(4'-N-hydroxy-N'-propylureidylphenyl)propyl)-  
5 4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-  
piperazine;
- 1-(3-(4'-N'-cyclopropyl-N-hydroxyureidylphenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;
- 10 1-(3-(3'-N-hydroxyureidylphenyl)propyl)-4-[2-(3-  
pyridyl)-thiazolidine-4-yl-carbonyl]piperazine;
- 1-(3-(3'-N-hydroxy-N'-methylureidylphenyl)propyl)-  
4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]  
piperazine;
- 15 1-(3-(3'-N'-ethyl-N-hydroxyureidylphenyl)propyl)-4-  
[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-  
piperazine;
- 1-(3-(3'-N'-cyclopropyl-N-hydroxyureidylphenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
20 carbonyl]piperazine;
- 1-(3-(3'-N'-p-chlorophenyl-N-hydroxyureidylphenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;
- 1-(3-(2'-N-hydroxyureidylphenyl)propyl)-4-[2-(3-  
25 pyridyl)-thiazolidine-4-yl-carbonyl]piperazine;
- 1-(3-(2'-N-hydroxy-N'-methylureidylphenyl)propyl)-  
4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-  
piperazine;

1-(3-(2'-N'-ethyl-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

5 1-(3-(2'-N-hydroxy-N'-phenylureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

1-(3-(2'-N'-butyl-N-hydroxyureidylphenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

10 Compound 38 (Hydroxamic Acid):

1-(3-(4'-N-hydroxy-N-methylcarboxamidophenyl)-propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;

Derivatives of Hydroxamic acid 38:

15 1-(3-(4'-N-hydroxycarboxamidophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;

1-(3-(4'-N-ethyl-N-hydroxycarboxamidophenyl)-propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;

20 1-(3-(4'-N-hydroxy-N-propylcarboxamidophenyl)-propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;

25 1-(3-(4'-N-cyclopropyl-N-hydroxycarboxamidophenyl)-propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;

1-(3-(3'-N-hydroxycarboxamidophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;

- 1-(3-(3'-N-hydroxy-N-methylcarboxamidophenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;
- 5 1-(3-(3'-N-ethyl-N-hydroxycarboxamidophenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;
- 1-(3-(3'-N-hydroxy-N-phenylcarboxamidophenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;
- 10 1-(3-(3'-N-butyl-N-hydroxycarboxamidophenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;
- 1-(3-(2'-N-hydroxycarboxamidophenyl)propyl)-4-[2-  
(3-pyridyl)thiazolidine-4-yl-carbonyl]piperazine;
- 15 1-(3-(2'-N-hydroxy-N-methylcarboxamidophenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;
- 1-(3-(2'-N-ethyl-N-hydroxycarboxamidophenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
20 carbonyl]piperazine;
- 1-(3-(2'-N-hydroxy-N-propylcarboxamidophenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;
- 25 1-(3-(2'-N-butyl-N-hydroxycarboxamidophenyl)-  
propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-  
carbonyl]piperazine;

Reverse Hydroxamic Acid of Compound 38:

1-(3-(4'-N-acetyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

5 Derivatives of hydroxamic acid 38:

1-(3-(4'-N-ethanoyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

10 1-(3-(4'-N-hydroxy-N-propanoyl-aminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

1-(3-(4'-N-butanoyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

15 1-(3-(3'-N-acetyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

20 1-(3-(3'-N-ethanoyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

1-(3-(3'-N-hydroxy-N-propanoyl-aminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

25 1-(3-(3'-N-butanoyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

1-(3-(2'-N-acetyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;



1-(3-(2'-N-ethanoyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine;

1-(3-(2'-N-hydroxy-N-propanoyl-aminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine; and

1-(3-(2'-N-butanoyl-N-hydroxyaminophenyl)propyl)-4-[2-(3-pyridyl)thiazolidine-4-yl-carbonyl]-piperazine.

10    **Example 5:**    **Preparation of Dihydropyridines As Dual Function Antagonists**


Dihydropyridines with PAF receptor antagonist activity, including those disclosed in UK Patent Application No. 2 233 974 A and WO 90/12015, can be modified to exhibit 5-lipoxygenase inhibiting activity. Nonlimiting examples of dihydropyridines modified to exhibit 5-lipoxygenase inhibiting activity are illustrated in Figure 5. Scheme 5 below illustrates three pathways for the preparation of dual function dihydropyridines. The first pathway sets out the preparation of the hydroxyureidylphenyl dihydropyridine 43. Reaction of the ketoamide 39 with the ketoester 40 and 2-chlorobenzaldehyde gives the nitroamide 41. Reduction of the nitroamide with zinc yields the aminoamide 42. Reaction of the aminoamide with triphosgene and methyl hydroxylamine gives the dual function antagonist 43.

Pathways two and three of Scheme 5 illustrate methods for the preparation of hydroxamidophenyldihydropyridine and hydroxamidodihydropyridine. The hydroxamidophenyldihydropyridine 46 is prepared as described above from the ketoamide 44, ketoester 40 and


- 55 -

2-chlorobenzaldehyde. The hydroxamidodihydropyridine 50 can be prepared from the ketoesters 47 and 40 along with 2-chlorobenzaldehyde.


Scheme 5



Scheme 5



Scheme 5



- 59 -

Nonlimiting examples of dual function dihydropyridines that can be prepared according to this process are:

Compound 43 (Hydroxyurea):

- 5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxy-N-methylureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

Derivatives of hydroxamic acid 43:

- 10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

- 15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-ethyl-N-hydroxyureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

- 20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxy-N-propylureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

- 25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-cyclopropyl-N-hydroxyureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxy-N-methylureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

- 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-ethyl-N-hydroxyureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-benzyl-N-hydroxyureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxy-N-propylureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-cyclopropyl-N-hydroxyureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxy-N-methylureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-ethyl-N-hydroxyureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-butyl-N-hydroxyureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

- 61 -

4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxy-N-propylureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

- 5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxy-N-phenylureidylphenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

Reverse hydroxyurea of Compound 43:

- 10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxy-N'-methylureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

Derivatives of Reverse Hydroxyurea of Compound 43:

- 15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

- 20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N'-ethyl-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

- 25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N'-cyclopropyl-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

- 30 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N'-butyl-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;



- 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxy-N'-methylureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;
- 10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N'-ethyl-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxy-N'-phenylureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;
- 20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N'-cyclopropyl-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;
- 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxy-N'-methylureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N'-ethyl-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxy-N'-propylureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N'-butyl-N-hydroxyureidylphenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

Compound 46 (Hydroxamic Acid):

15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxy-N-methylcarboxamidophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

Derivatives of Hydroxamic acid 46:

20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxycarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-ethyl-N-hydroxycarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

30 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxy-N-propylcarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

- 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-butyl-N-hydroxycarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxycarboxamidophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxy-N-methylcarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;
- 15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-ethyl-N-hydroxycarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxy-N-propylcarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;
- 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-cyclopropyl-N-hydroxycarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;
- 25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxycarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

- 65 -

4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxy-N-methylcarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-ethyl-N-hydroxycarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxy-N-propylcarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-butyl-N-hydroxycarboxamidophenyl)aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

Reverse Hydroxamic Acid of Compound 46:

20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-acetyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-ethanoyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-hydroxy-N-propanoylaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

30 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(4-N-

- 66 -

butanoyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-acetyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-ethanoyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-hydroxy-N-propanoylaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(3-N-butanoyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-acetyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-ethanoyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

- 67 -

4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-hydroxy-N-propanoylaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

- 5 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[(2-N-butanoyl-N-hydroxyaminophenyl)-aminocarbonyl]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)-phenyl]-1,4-dihydropyridine;

Compound 50 (Hydroxamic Acid):

- 10 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[4-N-hydroxy-N-methylcarboxamido]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

Derivatives of Hydroxamic Acid 50:

- 15 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[4-N-hydroxycarboxamido]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

- 20 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[4-N-ethyl-N-hydroxycarboxamido]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine;

4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[4-N-hydroxy-N-phenylcarboxamido]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine; and


- 25 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-[4-N-butyl-N-hydroxycarboxamido]-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-1,4-dihydropyridine.

- 68 -

**Example 6:** Preparation of Propenyl Carboxamide  
Hydroxyurea and Hydroxamic acid  
Derivatives with PAF Receptor  
Antagonist Activity and 5-Lipoxygenase  
Inhibiting Activity.







Propenyl carboxamides with PAF receptor antagonist activity can be modified into dual function antagonists with 5-lipoxygenase inhibiting activity, including those disclosed in Gutherie, G. L., et al., J. Med. Chem., 33, 2857 (1990); and European Patent Application No. 298466 A2. Examples of propenyl carboxamides with dual function PAF receptor antagonism and 5-LO inhibiting activity are illustrated in Figure 6. These compounds can be synthesized as illustrated in Scheme 6 below. The nitro or halogenoaniline **51** is reacted with the nitrile **52** to give the aniline **53**. Ring closure under acidic conditions then gives the indole **54**. The nitrile moiety of indole **54** is reduced with diisobutylaluminum hydride to give the aldehyde **55**. Conversion of the aldehyde **55** to the olefin with the Horner-Emmons Reagent gives the ester **56** which is then hydrolyzed to the acid **57**. Amidation of **57** through the acid chloride with R-3-(4-aminopentyl)pyridine (shown in scheme 6) gives the amide **58**. When R is a nitro group as in **59**, it is reduced with zinc metal to the amine and then converted to the hydroxyurea **61** with triphosgene and methyl hydroxylamine. When R is halogen as in **62** the aromatic ring can be metalated and carboxylated to produce the acid **63**. Conversion to the acid chloride and treatment with methyl hydroxylamine then yields the hydroxamic acid **64**.

### Scheme 6







## Scheme 6

Hydroxyureas:Hydroxamates:


Scheme 6



Following the same methodology as for the indole series (i.e. I), benzothiophene II can be converted to the following hydroxamates and hydroxyureas.



70



71

- 72 -

In a similar fashion, thiophene analogues can be prepared as shown in 65 through 69. These in turn can be converted to the hydroxyureas such as 70 or the hydroxamic acids such as 71.

- 5 Nonlimiting examples of dual function propenyl carboxamides that can be prepared according to this process are:

Compound 61 (Hydroxyurea):

- 10 [R-(E)]-6-(N-hydroxy-N-methylureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

Derivatives of Hydroxyurea 61:

- 15 [R-(E)]-6-(N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-6-(N-ethyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 20 [R-(E)]-6-(N-hydroxy-N-phenylureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-6-(N-butyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 25 [R-(E)]-7-(N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 30 [R-(E)]-7-(N-hydroxy-N-methylureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 73 -

[R-(E)]-7-(N-benzyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

5 [R-(E)]-7-(N-hydroxy-N-propylureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-7-(N-butyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

10 [R-(E)]-4-(N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

15 [R-(E)]-4-(N-hydroxy-N-methylureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-4-(N-ethyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

20 [R-(E)]-4-(N-hydroxy-N-propylureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-4-(N-butyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

25 [R-(E)]-5-(N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 74 -

[R-(E)]-5-(N-hydroxy-N-methylureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

5 [R-(E)]-5-(N-ethyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-5-(N-hydroxy-N-propylureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

10 [R-(E)]-5-(N-butyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

Reverse Hydroxyurea of Compound 61:

15 [R-(E)]-6-(N'-ethyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

Derivatives of Reverse Hydroxyurea of Compound 61:

20 [R-(E)]-6-(N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-6-(N'-benzyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

25 [R-(E)]-6-(N'-p-chlorophenyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-6-(N'-butyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 75 -

[R-(E)]-7-(N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

5 [R-(E)]-7-(N'-cyclopropyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)-butyl]-2-propenamide;

[R-(E)]-7-(N'-ethyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

10 [R-(E)]-7-(N'-butylamido)-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)-butyl]-2-propenamide;

15 [R-(E)]-4-(N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-4-(N'-ethyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

20 [R-(E)]-4-(N'-benzyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-4-(N'-butyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

25 [R-(E)]-5-(N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 76 -

[R-(E)]-5-(N'-cyclopropyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

5 [R-(E)]-5-(N'-ethyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-5-(N'-butyl-N-hydroxyureidyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

10 Compound 64 (Hydroxamic Acid):

[R-(E)]-6-(N-hydroxy-N-methylcarboxamido)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

15 5-[4'-(3-(N-hydroxy-N-methylureidylmethyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo-[2,1-a]isoquinoline;

Compound 70 (Hydroxyurea):

20 [R-(E)]-6-(N-hydroxy-N-methylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

Derivatives of Hydroxyurea 70:

[R-(E)]-6-(N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

25 [R-(E)]-6-(N-ethyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 77 -

[R-(E)]-6-(N-hydroxy-N-propylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

5 [R-(E)]-6-(N-cyclopropyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-7-(N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

10 [R-(E)]-7-(N-hydroxy-N-methylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

15 [R-(E)]-7-(N-ethyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-7-(N-hydroxy-N-propylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

20 [R-(E)]-7-(N-butyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-4-(N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

25 [R-(E)]-4-(N-hydroxy-N-methylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;



- 78 -

[R-(E)]-4-(N-ethyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

5 [R-(E)]-4-(N-hydroxy-N-propylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-4-(N-cyclopropyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

10 [R-(E)]-5-(N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

15 [R-(E)]-5-(N-hydroxy-N-methylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-5-(N-ethyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

20 [R-(E)]-5-(N-hydroxy-N-propylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

[R-(E)]-5-(N-butyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

25 Reverse Hydroxyurea of Compound 70:

[R-(E)]-6-(N-hydroxy-N'-methylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

Derivatives of Reverse Hydroxyurea of Compound 70:

- [R-(E)]-6-(N-hydroxyureidyl)-3-pentyl-2-benzo[b]-thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;
- 5 [R-(E)]-6-(N'-ethyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;
- [R-(E)]-6-(N-hydroxy-N'propylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;
- 10
- [R-(E)]-6-(N'-cyclopropyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;
- [R-(E)]-7-(N-hydroxyureidyl)-3-pentyl-2-benzo[b]-thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;
- 15
- [R-(E)]-7-(N-hydroxy-N'-methylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;
- [R-(E)]-7-(N'-ethyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;
- 20
- [R-(E)]-7-(N-hydroxy-N'-propylureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;
- 25
- [R-(E)]-7-(N'-butyl-N-hydroxyureidyl)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide;

- 80 -

[R-(E)]-4-(N-hydroxyureidyl)-3-pentyl-2-benzo[b]-  
thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-  
propenamide;

5 [R-(E)]-4-(N'-ethyl-N-hydroxyureidyl)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)benzyl]-  
2-propenamide;

[R-(E)]-4-(N'-benzyl-N-hydroxyureidyl)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

10 [R-(E)]-4-(N'-cyclopropyl-N-hydroxyureidyl)-3-  
pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-  
pyridyl)butyl]-2-propenamide;

15 [R-(E)]-4-(N'-butyl-N-hydroxyureidyl)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

[R-(E)]-5-(N-hydroxyureidyl)-3-pentyl-2-benzo[b]-  
thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-  
propenamide;

20 [R-(E)]-5-(N-hydroxy-N'-methylureidyl)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

[R-(E)]-5-(N'-ethyl-N-hydroxyureidyl)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

25 [R-(E)]-5-(N'-cyclopropyl-N-hydroxyureidyl)-3-  
pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-  
pyridyl)butyl]-2-propenamide;

[R-(E)]-5-(N'-butyl-N-hydroxyureidyl)-3-pentyl-2-

- 81 -

benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

Compound 71 (Hydroxamic Acid):

5 [R-(E)]-6-(N-hydroxy-N-methylcarboxamido)-3-pentyl-  
2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-  
butyl]-2-propenamide;

Derivatives of Hydroxamic Acid 71:

10 [R-(E)]-6-(N-hydroxycarboxamido)-3-pentyl-2-benzo-  
[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-  
propenamide;

[R-(E)]-6-(N-benzyl-N-hydroxycarboxamido)-3-pentyl-  
2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-  
butyl]-2-propenamide;

15 [R-(E)]-6-(N-hydroxy-N-propylcarboxamido)-3-pentyl-  
2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-  
butyl]-2-propenamide;

[R-(E)]-6-(N-butyl-N-hydroxycarboxamido)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

20 [R-(E)]-7-(N-hydroxycarboxamido)-3-pentyl-2-benzo-  
[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-  
propenamide;

25 [R-(E)]-7-(N-hydroxy-N-methylcarboxamido)-3-pentyl-  
2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-  
butyl]-2-propenamide;

[R-(E)]-7-(N-ethyl-N-hydroxycarboxamido)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

- 82 -

R-(E)]-7-(N-hydroxy-N-propylcarboxamido)-3-pentyl-  
2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-  
butyl]-2-propenamide;

5 R-(E)]-7-(N-butyl-N-hydroxycarboxamido)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

[R-(E)]-4-(N-hydroxycarboxamido)-3-pentyl-2-benzo-  
[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-  
propenamide;

10 [R-(E)]-4-(N-hydroxy-N-methylcarboxamido)-3-pentyl-  
2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-  
butyl]-2-propenamide;

R-(E)]-4-(N-ethyl-N-hydroxycarboxamido)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
15 2-propenamide;

R-(E)]-4-(N-hydroxy-N-propylcarboxamido)-3-pentyl-  
2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-  
butyl]-2-propenamide;

20 R-(E)]-4-(N-butyl-N-hydroxycarboxamido)-3-pentyl-2-  
benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-  
2-propenamide;

[R-(E)]-5-(N-hydroxycarboxamido)-3-pentyl-2-benzo-  
[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-  
propenamide;

25 [R-(E)]-5-(N-hydroxy-N-methylcarboxamido)-3-pentyl-  
2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-  
butyl]-2-propenamide;

- 83 -

R-(E)]-5-(N-benzyl-N-hydroxycarboxamido)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-butyl]-2-propenamide;

5 R-(E)]-5-(N-hydroxy-N-propylcarboxamido)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)-butyl]-2-propenamide; and

R-(E)]-5-(N-butyl-N-hydroxycarboxamido)-3-pentyl-2-benzo[b]thiophene-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide.

10 **Example 7:** Preparation of Hydroxyurea and Hydroxamic Acid Derivatives of Kadsurenone Analogs with PAF Receptor Antagonist Activity and 5-Lipoxygenase Inhibiting Activity.

15 Kadsurenone derivatives with PAF receptor antagonist activity, including those reported in Shen, et al., Proc. Natl. Acad. Sci. U.S.A., **82**, 672(1985) and Ponpipom, et al., J. Med. Chem., **30**, 136 (1987) can be converted into dual function  
20 antagonists by the addition of R<sup>1</sup> groups at bulk tolerating areas on the molecule. Examples of kadsurenone derivatives modified to exhibit 5-lipoxygenase activity according to the present invention are illustrated in Figures 7 and 7a.  
25 Processes for the preparation of compounds illustrated in Figures 7 and 7a are set out in Schemes 7 and 7a, respectively, below.


Referring to Scheme 7, kadsurenone derivative 81 is prepared from allylic alcohol 74  
30 and phenol 75 to give the diaryl ether 76. Cyclization of 76 with diethylaniline provides the dihydrobenzofuran 77 which is subsequently oxidized with lead tetraacetate to give the derivative 78. Removal of the ether protecting group yields the  
35 phenol 79. Reaction of the sodium salt of phenol

- 84 -

79 with chloroethylamine gives the amine 80 which is converted to the hydroxyurea 81 in the standard manner.


Referring to Figure 7a, kadsurenone derivative  
5 88 is prepared from the allylic alcohol 82 and the phenol 83 as illustrated.

Scheme 7





Scheme 7a



Nonlimiting examples of dual function kadsurenone derivatives that can be prepared according to this process are:

Compound 88 (Hydroxyurea):

- 5 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-methylureidyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

Derivatives of Hydroxyurea 88:

- 10 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-propylureidyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-phenylureidyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 15 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-n-pentylureidyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 20 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-methylureidyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-propylureidyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 25 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-phenylureidyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 88 -

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N-  
pentylureidyl)-3'-methoxyphenyl]-2,3,3A,6-  
tetrahydro-6-oxobenzofuran;

5 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-benzyl-N-  
hydroxyureidyl)-3'-methoxyphenyl]-2,3,3A,6-  
tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-n-butyl-N-  
hydroxyureidyl)-3'-methoxyphenyl]-2,3,3A,6-  
tetrahydro-6-oxobenzofuran;

10 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N-  
n-propylamido)-3'-methoxyphenyl]-2,3,3A,6-  
tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N-  
methylureidyl)-3'-methoxyphenyl]-2,3,3A,6-  
15 tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N-  
propylureidyl)-3'-methoxyphenyl]-2,3,3A,6-  
tetrahydro-6-oxobenzofuran;

20 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N-  
phenylureidyl)-3'-methoxyphenyl]-2,3,3A,6-  
tetrahydro-6-oxobenzo-furan;

Derivatives of Reverse Hydroxyurea of Compound 88:

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-  
N'-cyclopropylureidyl)-4'-methoxyphenyl]-2,3,3A,6-  
25 tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-  
N'-benzylureidyl)-4'-methoxyphenyl]-2,3,3A,6-  
tetrahydro-6-oxobenzofuran;

- 89 -

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N'-n-butylureidyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

5 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N'-cyclopropylureidyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N'-benzylureidyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

10 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N'-n-butylureidyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

Hydroxamic acid derivatives of Compound 88:

15 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-n-butylcarboxamido)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-cyclopropylcarboxamido)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

20 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N-cyclopropylcarboxamido)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

Methylene Spacer Derivatives of Hydroxyurea 88:

25 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-methylureidylmethyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-phenylureidylmethyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 90 -

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(*N*-hydroxy-*N*-n-pentylureidylmethyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

5 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N*-methylureidylmethyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N*-phenylureidylmethyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

10 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N*-isopropylureidylmethyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

Methylene spacer derivatives of reverse hydroxyurea  
88:

15 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(*N*-hydroxy-*N'*-methylureidylmethyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(*N*-hydroxy-*N'*-phenylureidylmethyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

20

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(*N*-hydroxy-*N'*-isopropylmethyl)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

25 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N'*-methylureidylmethyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N'*-phenylureidylmethyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 91 -

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N'-isobutylureidylmethyl)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

Compound 81 (hydroxyurea):

- 5 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-methylureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

Derivatives of hydroxyurea 81:

- 10 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-propylureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-isobutylureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 15 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-phenylureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 20 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-methylureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-isopropylureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 25 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxy-N-phenylureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N-hydroxy-N-propylureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 92 -

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N*-isobutylureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

5 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N*-sec-propylureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N*-isobutylcarboxamidoethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

10 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-ethyl-*N*-hydroxycarboxamidoethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

15 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-hydroxy-*N*-methylureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-cyclopropyl-*N*-hydroxyureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

20 *rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(*N*-benzyl-*N*-hydroxyureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

Hydroxamic Acid Derivatives of Compound 81:

25 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(*N*-cyclopropyl-*N*-hydroxycarboxamido)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(*N*-butyl-*N*-hydroxycarboxamido)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

Derivatives of Reverse Hydroxyurea of Compound 81:

*rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N'-cyclopropyl-N-hydroxyureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- 5 *rac*-5-allyl-3A-methoxy-3-methyl-2-[3'-(N-hydroxyureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- rac* -5-allyl-3A-methoxy-3-methyl-2-[3'-(N'-n-butyl-N-hydroxyureidylethoxy)-4'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;
- 10

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N'-cyclopropyl-N-hydroxyureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;

- rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N'-benzyl-N-hydroxyureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran;
- 15

*rac*-5-allyl-3A-methoxy-3-methyl-2-[4'-(N'-n-butyl-N-hydroxyureidylethoxy)-3'-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran

- 20 **Example 8:** Dual Function Dioxabicyclo[3.3.0]octanes

- Dioxabicyclo[3.3.0]octanes with PAF receptor antagonist activity can be modified to exhibit 5-lipoxygenase inhibiting activity by the addition of an R<sup>1</sup> group to a bulk tolerating location on the molecule. Nonlimiting examples of dual function dioxabicyclo[3.3.0]octanes are illustrated in Figure 8. Nonlimiting examples of specific dioxabicyclo[3.3.0]octanes include:
- 25



*rac-trans*-2-[3',4'-dimethoxy-5'-(N-hydroxy-N-methylureidyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo[3.3.0]octane;

5 *rac-trans*-2-[3',4'-dimethoxy-5'-(N-hydroxy-N-phenylureidyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo-[3.3.0]octane;

*rac-trans*-2-[3',4'-dimethoxy-5'-(N-cyclopropyl-N-hydroxyureidyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo[3.3.0]octane;

10 *rac-trans*-2-[3',4'-dimethoxy-5'-(N-hydroxy-N'-methylureidyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo-[3.3.0]octane;

15 *rac-trans*-2-[3',4'-dimethoxy-5'-(N'-butyl-N-hydroxyureidyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo-[3.3.0]octane;

*rac-trans*-2-[3',4'-dimethoxy-5'-(N-hydroxy-N'-phenylureidyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo-[3.3.0]octane;

20 *rac-trans*-2-[3',4'-dimethoxy-5'-(N-hydroxy-N-methylureidylmethyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo[3.3.0]octane;

*rac-trans*-2-[3',4'-dimethoxy-5'-(N-hydroxy-N-phenylureidylmethyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo[3.3.0]octane;

25 *rac-trans*-2-[3',4'-dimethoxy-5'-(N-hydroxy-N-propylureidylmethyl)phenyl]-6-(3",4",5"-trimethoxyphenyl)-1,5-dioxabicyclo[3.3.0]octane;

*rac-trans*-2-[3',4'-dimethoxy-5'-(N-hydroxy-N'-

- 95 -

methylureidylmethyl)phenyl]-6-(3",4",5"-  
trimethoxyphenyl)-1,5-dioxabicyclo[3.3.0]octane;

*rac-trans*-2-[3',4'-dimethoxy-5'-(N'-butyl-N-  
hydroxyureidylmethyl)phenyl]-6-(3",4",5"-  
5 trimethoxyphenyl)-1,5-dioxabicyclo[3.3.0]octane;  
and

*rac-trans*-2-[3',4'-dimethoxy-5'-(N'-benzyl-N-  
hydroxyureidylmethyl)phenyl]-6-(3",4",5"-  
trimethoxyphenyl)-1,5-dioxabicyclo[3.3.0]octane.

10 **Example 9:** Dual Function Antagonists with  
Oxaalkane, Thioalkane, Quinolylmethyl  
Ether, and Amidohydroxyurea Moieties

Using the procedures described above for  
the preparation of oxaalkane, thioalkane,  
15 quinolylmethoxy, and amidohydroxyurea moieties, a  
wide variety of dual function antagonists can be  
prepared that have both PAF receptor antagonist  
activity and 5-lipoxygenase inhibiting activity.

Specific nonlimiting examples are listed  
20 below. The PAF receptor antagonist that is used as  
the starting material for the dual function  
antagonist follows the compound name in  
parenthesis.

4-{6-(2-chlorophenyl)-11-methylcyclopentyl-  
25 [1,5:4,5] thieno [3,2-f] [1,3] imidazolo [3,2-a]-  
[1,4]diazpi-n-3-ylmethyl}-4-methoxy-3,4,5,6-  
tetrahydro-2H-pyran [and 2H-thiopyran] (from  
compound 2).

5-[4-3(4-methoxy-3,4,5,6-tetrahydro-2H-  
30 pyra-4-nyl)-4,5-dimethoxyphenylethyl)phenyl]2,3-  
dihydroimidazo[2,1-a]isoquinoline (from compound  
17) [and 2H-thiopyran analog.]

N-[4-(3-4-methoxy-3,4,5,6-tetrahydro-2H-  
pyra-4-nyl)phenoxyethyl)phenyl]-3-(3-pyridyl)1H,

3H pyrrolo[1,2-C]thiazole-7-carboxamide (from compound 28) [and 2H-thiopyran analog.]

5 N-[3-(4-methoxy-3,4,5,6-tetrahydro-2H-pyra-4-nyl)phenyl]-3-(3-pyridyl) 1H,3H-pyrrolo[1,2-C]thiazole-7-carboxamide (from compound 28) [and 2H-thiopyran analog.]

10 [R-(E)]-6-(3-(4-methoxy-3,4,5,6-tetrahydro-2H-thiopyra-4-nyl)phenoxy)methyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide (from compound 63).

6-(2-chlorophenyl)-3-(2-quinolylmethoxymethyl-11-methylcyclopentyl[1,5:4,5]thieno[3,2-f][1,3]imidazolo[3,2-a][1,4]-diazepine (from compound 2).

15 5-[4-(3-(2-quinolylmethoxymethyl)-4,5-dimethoxyphenylethyl)phenyl]-2,3-dihydroimidazo-[2,1-a]isocoquinoline (from compound 17).

20 N[4-(3-(2-quinolylmethoxymethyl)-phenyl]-3-(3-pyridyl) 1H,3H-pyrrolo[1,2-C]thiazole-7-carboxamide (from compound 28).

25 N-[4-(3-(2-quinolylmethoxy)-phenyl]-3-(3-pyridyl) 1H,3H-pyrrolo[1,2-C]thiazole-7-carboxamide [R-(E)-6-(2-quinolylmethoxy)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide

[R-(E)]-6-(2-quinolylmethoxymethyl)-3-pentyl-1-methyl-2-indole-N-[1-methyl-4-(3-pyridyl)butyl]-2-propenamide (from compound 63).

30 Amidohydroxyureas can be prepared, for example, from amine compounds numbered 4, 13, 72, 24, 60, and 87.

35 6-(2-chlorophenyl)-3-(N<sup>3</sup>-hydroxy-N-methyl ureidylacetyl)aminomethyl-11-methylcyclopentyl [1,5:4,5]thieno[3,2-f][1,3]imidazolo[3,2-a][1,4]-diazepine (from compound 4).

5-[4,5-dimethoxy-3-(N<sup>3</sup>-hydroxy-N<sup>3</sup>-methylureidylacetyl)amino)phenylethyl)phenyl]-2,3-

- 97 -

dihydroimidazo[2,1-a]isoquinoline (from compound 13).

5-[4,5-dimethoxy-3-(N<sup>3</sup>-hydroxy-N<sup>3</sup>-methyl-ureidylacetyl)aminomethyl)phenylethyl)phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline (compound 72).

N-(4-(N<sup>3</sup>-hydroxy-N<sup>3</sup>-butylureidylacetyl)amino phenyl)-3-(3-pyridyl)-1H-pyrrolo[1,2-C]thiazole-7-carboxymide (compound 24).

9R-(E)]-5-(N<sup>3</sup>-hydroxy-N<sup>3</sup>-ethylureidyl-acetyl)methylamino-3-entyl-1-methyl-2-indole-N-[10-methy-4-(3-pyridyl)butyl]-2-propenamide (compound 6).

rac-5-allyl-3-methoxy-3-methyl-2-[3-(N<sup>3</sup>-hydroxy-N<sup>3</sup>-butylureidylacetyl)amino-4-methoxyphenyl]-2,3,3A,6-tetrahydro-6-oxobenzofuran (from 63).

#### F. Stereochemistry

It is sometimes found that one or more enantiomers of a biologically active compound is more active, and perhaps less toxic, than other enantiomers of the same compound. Such enantiomerically enriched compounds are often preferred for pharmaceutical administration to humans. For example, it has been discovered that trans-2,5-diaryl tetrahydrothiophene and trans-2,5-diaryl tetrahydrofuran are often more active PAF receptor antagonists than their cis counterparts.

One of ordinary skill in the art can easily separate the enantiomers of the disclosed compounds using known procedures, and can evaluate the biological activity of the isolated enantiomer using methods disclosed herein or otherwise known. Through the use of chiral NMR shift reagents, polarimetry, or chiral HPLC, the optical enrichment of the compound can be determined.

- 98 -

Classical methods of resolution include a variety of physical and chemical techniques. Often the simplest and most efficient technique is fractional recrystallization.

5           When recrystallization fails to provide material of acceptable optical purity, other methods can be evaluated. If the compound is basic, one can use chiral acids that form diastereomeric mixtures that may possess  
10 significantly different solubility properties. Nonlimiting examples of chiral acids include malic acid, mandelic acid, dibenzoyl tartaric acid, 3-bromocamphor-8-sulfonic acid, 10-camphorsulfonic acid, and di-p-toluoyltartaric acid. Similarly,  
15 acylation of a free hydroxyl group with a chiral acid also results in the formation of diastereomeric mixtures whose physical properties may differ sufficiently to permit separation.

          Small amounts of enantiomerically enriched  
20 compounds can be obtained or purified by passing the racemic mixture through an HPLC column that has been designed for chiral separations, including cyclodextrin bonded columns marketed by Rainin Corporation.

## 25   II.   Evaluation of Biological Activity

          A wide variety of biological assays have been used to evaluate the ability of a compound to act as a PAF receptor antagonist, including the ability of the compound to bind to PAF receptors,  
30 and the effect of the compound on various PAF mediated pathways. Any of these known assays can be used to evaluate the ability of the compounds disclosed herein to act as PAF receptor antagonists.

35           For example, PAF is known to induce hemoconcentration and increased permeability of

- 99 -

microcirculation leading to a decrease in plasma volume. PAF mediated acute circulatory collapse can be used as the basis of an assay to evaluate the ability of a compound to act as a PAF

5 antagonist, by analyzing the effect of the compound on PAF induced decreased plasma volume in an animal model such as mouse.

Endotoxemia causes the release of chemical mediators including eicosanoids, PAF, and tumor  
10 necrosis factor (TNF) that stimulate a variety of physiologic responses including fever, hypotension, leukocytosis, and disturbances in glucose and lipid metabolism. Endotoxemia can result in severe shock and death. Endotoxin-induced mouse mortality is a  
15 useful animal model to evaluate the pharmacological effect of compounds on endotoxic shock.

Two other common assays used to evaluate the ability of a compound to act as a PAF receptor antagonist are platelet aggregation in vitro and  
20 hypotension in rats (Shen, et al., "The Chemical and Biological Properties of PAF Agonists, Antagonists, and Biosynthetic Inhibitors", Platelet-Activating Factor and Related Lipid Mediators, F. Snyder, Ed. Plenum Press, New York,  
25 NY 153 (1987).)

A wide variety of biological assays have also been used to evaluate the ability of a compound to inhibit the enzyme 5-lipoxygenase. For example, a cytosol 5-lipoxygenase of rat basophilic  
30 leukemia cells (RBL) has been widely utilized in studies on leukotriene biosynthesis. Compounds that inhibit 5-lipoxygenase decrease the levels of leukotrienes.

Another biological assay used to evaluate  
35 the ability of a compound to inhibit the enzyme 5-lipoxygenase is based on the classic pharmacological model of inflammation induced by

- 100 -

the topical application of arachidonic acid to the mouse ear. On application, arachidonic acid is converted by 5-lipoxygenase to various leukotrienes (and other mediators), which induce changes in blood flow, erythema, and increase vasodilation and vasopermeability. The resulting edema is measured by comparing the thickness of the treated ear to a control ear. Agents that inhibit 5-lipoxygenase reduce the edematous response, by lowering the amounts of biochemical mediators formed from arachidonic acid.

Detailed procedures for assays that can be used to evaluate the PAF and 5-lipoxygenase inhibiting activity of the compounds disclosed herein are provided below.

**Example 10: Ability of Dual Function Antagonist to Bind to PAF Receptors**

**a) Preparation of Human Platelet Membranes:**

Human platelet membranes can be prepared from platelet concentrates obtained from the American Red Cross Blood Services (Dedham, MA). After several washes with platelet wash solution (150 mM NaCl, 10 mM Tris, and 2 mM EDTA, pH 7.5), the platelet pellets are resuspended in 5 mM MgCl<sub>2</sub>, 10 mM Tris, and 2 mM EDTA at pH 7.0. The cells are then quickly frozen with liquid nitrogen and thawed slowly at room temperature. The freezing and thawing procedure should be repeated at least three times. For further fractionation of membrane fragments, the lysed membrane suspension is layered over the top of a discontinuous sucrose density gradient of 0.25, 1.03, and 1.5 M sucrose prepared in 10 mM MgCl<sub>2</sub>, 10 mM Tris and 2 mM EDTA, pH 7.0, and centrifuged at 63,500 x g for 2 hr. The membrane fractions banding between 0.25 and 1.03 M (membrane A) and between 1.03 and 1.5 M (membrane

- 101 -

B) are collected separately. The protein concentration of the membrane preparations is determined by Lowry's method with bovine serum albumin (BSA) as the standard. The membranes are  
5 then separated into smaller fractions (4 ml each) and stored at -80° C and thawed before use.

b) [<sup>3</sup>H]PAF Binding inhibition:

The ability of [<sup>3</sup>H]PAF to bind to specific receptors on human platelet membranes is evaluated  
10 at optimal conditions at pH 7.0 and in the presence of 10 mM MgCl<sub>2</sub>. Membrane protein (100 ug) is added to a final 0.5 ml solution containing 0.15 pmol (0.3 nM concentration) of [<sup>3</sup>H]PAF and a known amount of unlabeled PAF or PAF receptor antagonist in 10  
15 mM MgCl<sub>2</sub>, 10 mM Tris and 0.25% BSA at pH 7.0. After incubation for four hours at 0°C, the bound and unbound [<sup>3</sup>H]PAF is then separated through a Whatman GF/C glass fiber filter under vacuum. No degradation of filter bound [<sup>3</sup>H]PAF has been  
20 detected under this assay condition. The nonspecific binding is defined as the total binding in the presence of excess unlabeled PAF (1 mM) where no further displacement is found with higher concentrations of either unlabeled PAF or PAF  
25 analogs or PAF receptor antagonists. The specific binding is defined as the difference between total binding and nonspecific binding.

To determine the relative potency of tested compounds, [<sup>3</sup>H]PAF binding in the presence of  
30 inhibitors is normalized in terms of percent inhibition by assigning the total binding in the absence of inhibitors as 0% inhibition and the total binding in the presence of 1 mM unlabeled PAF as 100%. The percent inhibition by the compound  
35 can be calculated by the formula expressed below:



- 102 -

% inhibition = [(Total binding - total binding in the presence of compound)/nonspecific binding] x 100%

5 The IC<sub>50</sub> is calculated as the concentration of the inhibitor necessary to obtain 50% inhibition of the specific [<sup>3</sup>H]PAF binding and is calculated by a nonlinear regression computer software program, GraphPad Inplot, version 3.0 (GraphPad software, San Diego, CA).

10 **Example 11: Effect of Compound on PAF-induced Hemoconcentration**

a) Animals

Female CD-1 mice, weighing 16-20 grams, can be obtained from Charles River Laboratory (Wilmington, MA). Tap water and rodent laboratory chow (5001, Purina Mills, St. Louis, MO) should be provided ad libitum, and the mice housed for an average of four days prior to use.

b) Hematocrit measurement

20 PAF (1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine, Sigma Chemical Co.) is dissolved in 0.25% bovine serum albumin (BSA) in 0.9% NaCl solution. Except for dose-response studies, 10 µg (10 ml/kg) of PAF solution is injected into the tail vein. Test compounds are dissolved in 0.5 DMSO saline solution and intravenously injected at 3 mg/kg body weight 15 minutes prior to PAF challenge. Thirty to fifty µL blood is collected by cutting the tail end into a heparinized micro-hematocrit tube (O.D. 1.50 mm) 15 minutes after PAF administration.

- 103 -

**Example 12: Effect of Compounds on Arachidonic  
Acid-induced Mouse Ear Edema**

a) Animals

5           The animals are obtained and treated as in  
Example 10 above.

b) Edema measurement

Arachidonic acid is applied to both ears of  
mice in 0.025 ml of freshly prepared vehicle  
10 (acetone:pyridine:water (97:2:1 v/v/v) and dried  
under a Sun-Lite Hitensity bulb. Except for  
dose-response studies, 0.5 mg of arachidonic acid  
is used for all applications. All test compounds  
are dissolved in 0.5% DMSO saline solution and  
15 intravenously injected at 3 mg/kg body weight 15  
minutes prior to arachidonic acid treatment.  
Animals are sacrificed by cervical dislocation at 1  
hour after topical application of arachidonic acid.  
A 7 mm-diameter disc of tissue is removed from each  
20 ear by means of a metal punch. Edema is measured  
by the average wet weight of the both ear tissues.

**Example 13: Effect of Compounds on  
Endotoxin-induced Mouse Mortality**

a) Animals

25           The mice are obtained and treated as in  
Example 10 above.

b) Mortality Measurement

Endotoxin (E. coli serotype 0127:B8,  
lipopolysaccharide, Sigma Chemical Co.) St. Louis,  
30 is freshly dissolved in 0.9% NaCl solution. Except  
for dose-response studies, endotoxin at 50 mg/kg is  
injected into the tail vein. Test compounds are  
dissolved in 0.5% DMSO saline solution and  
intravenously injected at 3 mg/kg body weight 15  
35 minutes prior to PAF challenge. Death occurs

- 104 -

typically within 12-36 hours. Mortality is recorded 48 hours after endotoxin challenge, as death rarely occurs after 48 hr. The extent of mouse mortality in response to varying concentrations of endotoxin within 48 hours after intravenous injection of endotoxin is evaluated.

**Example 14: Effect of Compounds on Cytosol 5-Lipoxygenase of Rat Basophile Leukemia Cells**

10 a) Enzyme preparation

Washed rat RBL cells ( $4 \times 10^8$ ) are suspended in 20 ml of 50 M potassium phosphate buffer at pH 7.4 containing 10% ethylene glycol/1 mM EDTA (Buffer A). The cell suspension is sonicated at 20 KHz for 15 30 seconds, and the sonicate centrifuged at 10000 x g for 10 minutes, followed by further centrifugation at 105000 x g for 1 hr. The supernatant solution (cytosol fraction) containing 5-lipoxygenase is stored at  $-70^\circ\text{C}$ . Protein 20 concentration is determined according to the procedure of Bradford (Bradford Dye Reagent) with bovine serum albumin as a standard.

b) Enzyme assay

For routine assay of 5-LO the mixture should 25 contain 50 mM potassium phosphate buffer at pH 7.4, 2 mM  $\text{CaCl}_2$ , 2 mM ATP, 25 M arachidonic acid (0.1 Ci) and enzyme (50-100 mg of protein) in a final volume of 200 L. The reaction is carried out at  $24^\circ\text{C}$  for 3 minutes. The mixture is extracted with 30 0.2 ml of an ice-cold mixture of ethyl ether:methanol: 0.2 M citric acid (30:4:1). The extract is subjected to thin-layer chromatography at  $-10^\circ\text{C}$  in a solvent system of petroleum ether:ethyl ether:acetic acid (15:85:0.1). The 35 silica gel zones corresponding to authentic

- 105 -

arachidonic acid and its metabolites are scrapped into scintillation vials for counting. The enzyme activity is expressed in terms of the amount of arachidonic acid oxygenated for 3 minutes.

5     III.   Pharmaceutical Compositions

          Humans, equine, canine, bovine and other animals, and in particular, mammals, suffering from disorders mediated by PAF or products of 5-lipoxygenase can be treated by administering to the  
10    patient an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable derivative or salt thereof in a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any  
15    appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid, cream, gel or solid form.

          As used herein, the term pharmaceutically  
20    acceptable salts or complexes refers to salts or complexes that retain the desired biological activity of the above-identified compounds and exhibit minimal undesired toxicological effects. Nonlimiting examples of such salts are (a) acid  
25    addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid,  
30    succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid; (b) base addition salts formed with  
35    polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper,

- 106 -

cobalt, nickel, cadmium, sodium, potassium, and the like, or with an organic cation formed from N,N-dibenzylethylene-diamine, D-glucosamine, ammonium, tetraethylammonium, or ethylenediamine; or (c)  
5 combinations of (a) and (b); e.g., a zinc tannate salt or the like.

The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a  
10 therapeutically effective amount without causing serious toxic effects in the patient treated. A preferred dose of the active compound for all of the above-mentioned conditions is in the range from about 0.01 to 300 mg/kg, preferably 0.1 to 100  
15 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient per day. A typical topical dosage will range from 0.01 - 3% wt/wt in a suitable carrier. The effective dosage range of the pharmaceutically acceptable  
20 derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means  
25 known to those skilled in the art.

The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing 1 to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage  
30 form. A oral dosage of 25-250 mg is usually convenient.

The active ingredient should be administered to achieve peak plasma concentrations of the active compound of about 0.01 -30  $\mu$ M,  
35 preferably about 0.1-10  $\mu$ M. This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient,

- 107 -

optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient.

The concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.

Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.

The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic

- 108 -

acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange  
5 flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various  
10 other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.

The active compound or pharmaceutically acceptable salt or derivative thereof can be  
15 administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and  
20 flavors.

The active compound or pharmaceutically acceptable derivatives or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that  
25 supplement the desired action, such as antibiotics, antifungals, antiinflammatories, or antiviral compounds.

Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical  
30 application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl  
35 alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers

- 109 -

such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or  
5 multiple dose vials made of glass or plastic.

If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).

In one embodiment, the active compounds are  
10 prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used,  
15 such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained  
20 commercially from Alza Corporation and Nova Pharmaceuticals, Inc.

Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those  
25 skilled in the art, for example, as described in U.S. Patent No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearyl phosphatidyl  
30 ethanolamine, stearyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of  
35 the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives are then introduced into the container. The container



- 110 -

is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

5            Modifications and variations of the present invention relating to compounds that act as PAF receptor antagonists and inhibitors 5-lipoxygenase methods for the treatment of disorders mediated by platelet activating factor and products of  
10 5-lipoxygenase, will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to come within the scope of the appended claims.

15    We claim.

- 111 -

1. A method for imparting 5-lipoxygenase inhibiting activity to a compound that is a PAF receptor antagonist to provide a dual function antagonist, comprising the addition of  $R^1$  to a bulk tolerating location on the compound, wherein  $R^1$  is:


(1) a hydroxamate or hydroxyurea of the formula:

$-R^2N(OM)C(O)N(R^3)R^4$ ,  $-R^2N(R^3)C(O)N(OM)R^4$ ,  
 $-R^2N(OM)C(O)R^4$ ,  $-R^2C(O)N(OM)R^4$ ,  $-N(OM)C(O)N(R^3)R^4$ ,  
 $-N(R^3)C(O)N(OM)R^4$ ,  $-N(OM)C(O)R^4$ , or  $-C(O)N(OM)R^4$ ;

(2) an amidohydroxyurea of the formula:

$-N(R^8)C(O)C(R^8)N(OM)C(O)NHR^9$ ,  
 $-C(O)N(R^8)C(R^8)N(OM)C(O)NHR^9$ ,  
 $-R^2N(R^8)C(O)C(R^8)N(OM)C(O)NHR^9$ ,  
 $-R^2C(O)N(R^8)C(R^8)N(OM)C(O)NHR^9$ ,  
 $-NHC(O)N(OM)C(R^8)C(O)N(R^8)_2$ ; or  
 $-NHC(O)N(OM)C(R^8)N(R^8)C(O)R^8$ ;


(3) an oxalkane of the structure:




wherein n and m are independently 1-4 ;

- 112 -

(4) a thioalkane of the structure:



or (5) a quinolylmethoxy of the structure:



wherein:

$R^2$  is alkyl, alkenyl, alkynyl, alkyaryl,  
 aralkyl, halo lower alkyl, halo lower alkyl, halo  
 lower alkynyl,  $-C^{1-10}$ alkyl(oxy) $C^{1-10}$ alkyl,  
 $-C^{1-10}$ alkyl(thio) $C^{1-10}$ alkyl,  $-N(R^3)C(O)$ alkyl,  
 $-N(R^3)C(O)$ alkenyl,  $-N(R^3)C(O)$ alkynyl,  
 $-N(R^3)C(O)(alkyl)oxy(alkyl)$ ,  $-N(R^3)C(O)(alkyl)thio$   
 $(alkyl)$ ,  $-N(R^3)C(O)N(alkyl)$ ,  $-N(R^3)C(O)N(alkenyl)$ ,  
 $-N(R^3)C(O)N(alkynyl)$ ,  $-N(R^3)C(O)N(alkyl)oxy(alkyl)$ ,  
 $-N(R^3)C(O)N(alkyl)thio(alkyl)$ ,  $-N(R^3)C(O_2)alkyl$ ,  
 $-N(R^3)C(O_2)alkenyl$ ,  $-N(R^3)C(O_2)alkynyl$ ,  
 $-N(R^3)C(O_2)(alkyl)oxy(alkyl)$ ,

- 113 -

-N(R<sup>3</sup>)C(O<sub>2</sub>)(alkyl)thio(alkyl), -OC(O<sub>2</sub>)alkyl,  
-OC(O<sub>2</sub>)alkenyl, -OC(O<sub>2</sub>)alkynyl,  
-OC(O<sub>2</sub>)(alkyl)oxy(alkyl), -OC(O<sub>2</sub>)(alkyl)thio(alkyl),  
-N(R<sup>3</sup>)C(S)alkyl, -N(R<sup>3</sup>)C(S)alkenyl,  
-N(R<sup>3</sup>)C(S)alkynyl, -N(R<sup>3</sup>)C(S)(alkyl)oxy(alkyl),  
-N(R<sup>3</sup>)C(S)(alkyl)thio(alkyl), -N(R<sup>3</sup>)C(S)N(alkyl),  
-N(R<sup>3</sup>)C(S)N(alkenyl), -N(R<sup>3</sup>)C(S)N(alkynyl),  
-N(R<sup>3</sup>)C(S)N(alkyl)oxy(alkyl),  
-N(R<sup>3</sup>)C(S)N(alkyl)thio(alkyl), -N(R<sup>3</sup>)C(S)S(alkyl),  
-N(R<sup>3</sup>)C(S)S(alkenyl),  
-N(R<sup>3</sup>)C(S)S(alkynyl), -N(R<sup>3</sup>)C(S)S(alkyl)oxy(alkyl),  
-N(R<sup>3</sup>)C(S)S(alkyl)thio(alkyl),  
-SC(S)S(alkyl), -SC(S)S(alkenyl), -SC(S)S(alkynyl),  
-SC(S)S(alkyl)oxy(alkyl), or  
-SC(S)S(alkyl)thio(alkyl);

R<sup>3</sup> and R<sup>4</sup> are independently alkyl, alkenyl, alkynyl, aryl, aralkyl, alkyaryl, hydrogen, C<sub>1-6</sub> alkoxy-C<sub>1-10</sub> alkyl, C<sub>1-6</sub> alkylthio-C<sub>1-10</sub> alkyl, and C<sub>1-10</sub> substituted alkyl (wherein the substituent is independently hydroxy or carbonyl, located on any of C<sub>1-10</sub>);


R<sup>8</sup> is H, lower alkyl, or lower alkenyl;

R<sup>9</sup> is H, halogen, lower alkoxy, or lower alkyl; and


M is hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable leaving group.

- 114 -


2. The method of claim 1, wherein the dual function antagonist is selected from the group consisting of:



3. The method of claim 1, wherein the dual function antagonist has the structure:




4. The method of claim 1, wherein the dual function antagonist is selected from the group consisting of:




$R^{12}$  is H, alkyl, aryl, or aralkyl.


5. The method of claim 1, wherein the dual function antagonist has the structure:





6. The method of claim 1, wherein the dual function antagonist is selected from the group consisting of:





7. The method of claim 1, wherein the dual function antagonist is selected from the group consisting of:



8. The method of claim 1, wherein the dual function antagonist is selected from the group consisting of:




9. The method of claim 1, wherein the dual function antagonist is selected from the group consisting of:





10. The method of claim 1, wherein the dual function antagonist has the structure:



11. The dual function antagonist of claim 3.

12. The dual function antagonist of claim 4.

13. The dual function antagonist of claim 5.

14. The dual function antagonist of claim 6.

15. The dual function antagonist of claim 7.

16. The dual function antagonist of claim 8.

17. The dual function antagonist of claim 9.

18. The dual function antagonist of claim 10.

19. The dual function antagonist of claim 11.

1/9





Figure 1

2/9




Figure 2

3/9






Figure 3

4/9




Figure 4

5/9




Figure 5

6/9




 $X = S, NCH_3$ 

Figure 6

7/9





Figure 7



8/9





Figure 7a

9/9




Figure 8